{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "62013a56-bbf0-47c9-a866-a793215b1c0b",
   "metadata": {},
   "source": [
    "# Extract all possible occurrences of ‚ÄúAudit & Inspection Rights‚Äù clause"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b8783ec7-c99b-4350-9bb1-0c0d3359a90b",
   "metadata": {},
   "source": [
    "## Load and Chunk \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "bac28630-548c-4a1a-af42-1138ef7350a8",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import UnstructuredWordDocumentLoader\n",
    "\n",
    "\n",
    "def load_and_chunk_document(docx_path):\n",
    "    \"\"\"Loads document and intelligently chunks while preserving section integrity.\"\"\"\n",
    "    loader = UnstructuredWordDocumentLoader(docx_path, mode=\"elements\")\n",
    "    data = loader.load()\n",
    "\n",
    "    # Extract text and clean it\n",
    "    text = \"\\n\".join([chunk.page_content.strip() for chunk in data if chunk.page_content.strip()])\n",
    "\n",
    "    #  chunking\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=10000,  # Large enough to capture a full clause\n",
    "        chunk_overlap=2000,  # Overlap to prevent split clauses\n",
    "        separators=[\"\\n\\n\", \"\\n\", \". \", \" \"],  # Prefer splitting at paragraphs or sentences\n",
    "    )\n",
    "    \n",
    "    chunks = text_splitter.split_text(text)\n",
    "    \n",
    "    return chunks\n",
    "\n",
    "# Load and chunk document\n",
    "docx_path = \"contract_interview.docx\"\n",
    "document_chunks = load_and_chunk_document(docx_path)\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "92b4286d-7eae-4877-88c8-5ee19d52ce1e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "17"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(document_chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "5ed58163-108b-4b06-b205-296ffb495668",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üîπüîπüîπ Chunk 1 (Length: 9850 characters):\n",
      "Exhibit 10.2\n",
      "CONFIDENTIAL\n",
      "CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH ‚Äú[***]‚Äù. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.\n",
      "API COMMERCIAL SUPPLY AGREEMENT\n",
      "by and between\n",
      ".\n",
      "and\n",
      ".\n",
      "Dated as of May 25, 2011\n",
      "API COMM ERCIAL SUPPLY AGREEMENT\n",
      "THIS API COMMERCIAL SUPPLY AGREEMENT (this ‚ÄúAgreement‚Äù) is entered into and dated as of the 25th day of May, 2011 (the ‚ÄúEffective Date‚Äù) by and between  ., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (‚Äú‚Äù), and ., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (‚Äú‚Äù).  and  are sometimes referred to herein individually as a ‚ÄúParty‚Äù and collectively as the ‚ÄúParties.‚Äù\n",
      "RECITALS\n",
      "WHEREAS,  is engaged in the research, development and commercialization of proprietary pharmaceutical products;\n",
      "WHEREAS,  is a company that has developed substantial expertise in manufacturing polyunsaturated fatty acids, including the Compound (as defined herein), for use in nutritional supplement and pharmaceutical products; and\n",
      "WHEREAS, the Parties desire to enter into a supply agreement pursuant to which  will manufacture a certain active pharmaceutical ingredient for .\n",
      "NOW, THEREFORE, in consideration of the foregoing recitals, mutual covenants, agreements, representations and warranties contained herein, the Parties hereby agree as follows:\n",
      "Article I\n",
      "Definitions\n",
      "‚ÄúAdditional Expansions‚Äù has the meaning in Section 3.1(a) of this Agreement.\n",
      "‚ÄúAdverse Event‚Äù has the meaning in Section 6.7(a) of this Agreement.\n",
      "‚ÄúAffiliate‚Äù means a corporation or non-corporate business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in control of another entity if: (a) it owns, directly or indirectly, at least fifty percent (50%) of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (b) it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity, as applicable, whether through the ownership or control of voting securities, by contract or otherwise.\n",
      "‚ÄúAgreement‚Äù means this API Commercial Supply Agreement, including all Schedules hereto. ‚Äú‚Äù has the meaning in the preamble of this Agreement.\n",
      "‚Äú Confidential Information‚Äù has the meaning provided in Section 13.1 of this Agreement.\n",
      "‚Äú Intellectual Property‚Äù means any and all Intellectual Property relating to the Product (as defined below) or the development or manufacture thereof that was (a) owned, licensed or controlled by  or  Affiliates as of the Effective Date, or (b) developed or acquired by  or  Affiliates after the Effective Date.\n",
      "‚Äú License‚Äù has the meaning provided in Section 8.3 of this Agreement.\n",
      "2\n",
      "‚ÄúAPI‚Äù means [***].\n",
      "‚ÄúAPI Price‚Äù has the meaning provided in Section 3.1(a) of this Agreement.\n",
      "‚ÄúAPI Product Developments‚Äù has the meaning provided in Section 8.2(a) of this Agreement. ‚ÄúAPI Specifications‚Äù mean all specifications set forth on Schedule 5.1 to this Agreement. ‚ÄúApproved Representatives‚Äù has the meaning provided in Section 5.4(a) of this Agreement.\n",
      "‚ÄúCalendar Quarter‚Äù means each three (3) month period beginning each January 1, April 1, July 1 and October 1 during the Term. The initial Calendar Quarter shall begin on the Effective Date and end on June 30, 2011, and the last Calendar Quarter shall end on the expiration or earlier termination date of the Term.\n",
      "‚ÄúCalendar Year‚Äù means each twelve (12) month period beginning each January 1 during the Term. The initial Calendar Year shall begin on the Effective Date and end on the first December 31 during the Term, and the last Calendar Year shall begin on January 1 of the last year of the Term and end on the expiration or earlier termination date of the Term.\n",
      "‚ÄúCertificate of Analysis‚Äù means a document identified as such and provided by  to  in the form set forth in Schedule 6.2 that (a) sets forth the analytical test results for a specified lot of API shipped to  or its designee hereunder and includes a certified quality control protocol, (b) states that such API is in conformance with the Drug Application and API Specifications, and (c) states that such API is manufactured in accordance with the API Specifications, Legal Requirements and cGMPs.\n",
      "‚ÄúCertificates‚Äù has the meaning provided in Section 6.2 of this Agreement.\n",
      "‚ÄúChange of Control‚Äù means any proposed transaction or series of transactions which shall result in (a) any Person other than a Party having direct or indirect ownership of more than fifty percent (50%) of the voting stock or assets of such Party or an Affiliate that controls such Party by Persons who are not shareholders of such Party or the Affiliate that controls such Party as of the Effective Date, or (b) the merger of a Party with or into a Third Party in a transaction in which such Party is not the surviving or acquiring Person.\n",
      "‚Äú‚Äù has the meaning in the preamble of this Agreement.\n",
      "‚Äú Approval(s)‚Äù means the approval of the Facility as a cGMP facility for the manufacture of the API by the FDA and, as applicable, by any other applicable Governmental Body having jurisdiction to approve the Facility.\n",
      "‚Äú Confidential Information‚Äù has the meaning provided in Section 13.2 of this Agreement.\n",
      "‚Äú Intellectual Property‚Äù means (a) all Intellectual Property owned, licensed or controlled by  as of the Effective Date, and (b) all Intellectual Property developed or acquired by  after the Effective Date that does not relate to the Product or the development or manufacture of the Product, except that Intellectual Property developed by  related to the API shall be included in  Intellectual Property.\n",
      "‚Äú‚Äôs Initial Minimum Capacity‚Äù has the meaning provided in Section 4.1 of this Agreement. 3\n",
      "‚Äú‚Äôs Minimum Capacity‚Äù has the meaning provided in Section 4.1 of this Agreement. ‚ÄúCMC‚Äù means the chemistry, manufacturing and controls section(s) and data in a Drug Application. ‚ÄúCommercial Launch Forecast‚Äù has the meaning provided in Section 2.4(a) of this Agreement. ‚ÄúCompound‚Äù means ethyl ester of eicosapentaenoic acid.\n",
      "‚ÄúConfidential Information‚Äù has the meaning provided in Section 13.3 of this Agreement.\n",
      "‚ÄúConsent‚Äù means any consent, authorization, permit, certificate, license or approval of, exemption by, or filing or registration with, any Governmental Body or other Person.\n",
      "‚ÄúCurrent Good Manufacturing Practices‚Äù or ‚ÄúcGMPs‚Äù means all applicable standards relating to manufacturing practices for intermediates, active pharmaceutical ingredients or finished pharmaceutical products, including without limitation (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 210 and 211, The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products, and Q7A Good Manufacturing Practice Guidance For Active Pharmaceutical Ingredients (ICH Q7A), and (b) the principles promulgated by any applicable Governmental Body having jurisdiction over the manufacture of the API, in the form of laws, rules or regulations, in each case as in effect at the Effective Date and as amended, promulgated or accepted by any applicable Governmental Body from time to time during the Term.\n",
      "‚ÄúDays‚Äù (whether or not the word is capitalized) means, except where specified otherwise, calendar days.\n",
      "‚ÄúDevelopment and Process Validation Plan‚Äù means the development and validation plan to be agreed to by the Parties within [***] days of the Effective Date.\n",
      "‚ÄúDMFs‚Äù has the meaning provided in Section 7.5 of this Agreement.\n",
      "‚ÄúDrug Application‚Äù means a ‚Äònew drug application‚Äô (as such term is used under the United States Federal Food, Drug and Cosmetic Act) filed with the FDA for the Product, including, without limitation, any supplements thereto, any product license or any equivalent drug application or similar pharmaceutical product approval for the Product administered by any foreign Governmental Body, or supplement, extension or renewal of any of the foregoing.\n",
      "‚ÄúEffective Date‚Äù has the meaning in the preamble of this Agreement.\n",
      "‚ÄúEffective Supply Date‚Äù means the date of completion of the Expansion in accordance with Sections 4.1 and 4.2 of this Agreement.\n",
      "‚ÄúExpansion‚Äù has the meaning set forth in Section 4.1 of this Agreement.\n",
      "‚ÄúFacility‚Äù means ‚Äôs manufacturing facility located at [***] (as the same may be expanded as provided herein), or such other FDA approved facility as agreed in writing by the Parties.\n",
      "‚ÄúFDA‚Äù means the United States Food and Drug Administration, or any successor agency thereof. ‚ÄúForce Majeure Event‚Äù has the meaning provided in Section 14.1 of this Agreement. 4\n",
      "‚ÄúGovernmental Body‚Äù means any nation or government, any state, province or other political subdivision thereof, any entity with legal authority to exercise executive, legislative, judicial, regulatory or administrative functions, or any division of the FDA (as applicable) and any other applicable counterpart agency or foreign equivalent that administers the Legal Requirements.\n",
      "‚ÄúIndemnified Party‚Äù has the meaning provided in Section 11.3 of this Agreement.\n",
      "‚ÄúIndemnifying Party‚Äù has the meaning provided in Section 11.3 of this Agreement.\n",
      "‚ÄúInitial Manufacturing Process‚Äù has the meaning provided in Section 5.4(a) of this Agreement. ‚ÄúInitial Term‚Äù has the meaning provided in Section 15.1 of this Agreement.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 2 (Length: 9655 characters):\n",
      "‚ÄúDMFs‚Äù has the meaning provided in Section 7.5 of this Agreement.\n",
      "‚ÄúDrug Application‚Äù means a ‚Äònew drug application‚Äô (as such term is used under the United States Federal Food, Drug and Cosmetic Act) filed with the FDA for the Product, including, without limitation, any supplements thereto, any product license or any equivalent drug application or similar pharmaceutical product approval for the Product administered by any foreign Governmental Body, or supplement, extension or renewal of any of the foregoing.\n",
      "‚ÄúEffective Date‚Äù has the meaning in the preamble of this Agreement.\n",
      "‚ÄúEffective Supply Date‚Äù means the date of completion of the Expansion in accordance with Sections 4.1 and 4.2 of this Agreement.\n",
      "‚ÄúExpansion‚Äù has the meaning set forth in Section 4.1 of this Agreement.\n",
      "‚ÄúFacility‚Äù means ‚Äôs manufacturing facility located at [***] (as the same may be expanded as provided herein), or such other FDA approved facility as agreed in writing by the Parties.\n",
      "‚ÄúFDA‚Äù means the United States Food and Drug Administration, or any successor agency thereof. ‚ÄúForce Majeure Event‚Äù has the meaning provided in Section 14.1 of this Agreement. 4\n",
      "‚ÄúGovernmental Body‚Äù means any nation or government, any state, province or other political subdivision thereof, any entity with legal authority to exercise executive, legislative, judicial, regulatory or administrative functions, or any division of the FDA (as applicable) and any other applicable counterpart agency or foreign equivalent that administers the Legal Requirements.\n",
      "‚ÄúIndemnified Party‚Äù has the meaning provided in Section 11.3 of this Agreement.\n",
      "‚ÄúIndemnifying Party‚Äù has the meaning provided in Section 11.3 of this Agreement.\n",
      "‚ÄúInitial Manufacturing Process‚Äù has the meaning provided in Section 5.4(a) of this Agreement. ‚ÄúInitial Term‚Äù has the meaning provided in Section 15.1 of this Agreement.\n",
      "‚ÄúIntermediate‚Äù means a material produced during steps in the synthesis of API that must undergo further molecular change or processing before it becomes API.\n",
      "‚ÄúIntellectual Property‚Äù means (a) patents, patent rights, provisional patent applications, patent applications, designs, registered designs, registered design applications, industrial designs, industrial design applications and industrial design registrations, including any and all divisions, continuations, continuations-in part, extensions, restorations, substitutions, renewals, registrations, revalidations, reexaminations, reissues or additions, including supplementary certificates of protection, of or to any of the foregoing items; (b) copyrights, copyright registrations, copyright applications, original works of authorship fixed in any tangible medium of expression, including literary works (including all forms and types of computer software, including all source code, object code, firmware, development tools, files, records and data, and all documentation related to any of the foregoing), musical, dramatic, pictorial, graphic and sculptured works; (c) trade secrets, technology, developments, discoveries and improvements, know-how, proprietary rights, formulae, confidential and proprietary information, technical information, techniques, inventions, designs, drawings, procedures, processes, models, formulations, manuals and systems, whether or not patentable or copyrightable, including all biological, chemical, biochemical, toxicological, pharmacological and metabolic material and information and data relating thereto and formulation, clinical, analytical and stability information and data which have actual or potential commercial value and are not available in the public domain; (d) trademarks, trademark registrations, trademark applications, service marks, service mark registrations, service mark applications, business marks, brand names, trade names, trade dress, names, logos and slogans, Internet domain names, and all goodwill associated therewith; and (e) all other intellectual property or proprietary rights worldwide, in each case whether or not subject to statutory registration or protection.\n",
      "‚ÄúLegal Requirements‚Äù means any and all local, municipal, state, provincial, federal and international laws, statutes, ordinances, rules or regulations now or hereafter enacted or promulgated by any Governmental Body applicable to the development, approval, manufacture, sale, shipment or licensing of any pharmaceutical products, ingredients for inclusion therein, or any aspect thereof, and the obligations of  or , as the context requires, under this Agreement, including, without limitation, applicable laws, statutes, ordinances, rules and regulations of South Korea, as well as the United States Federal Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder.\n",
      "‚ÄúLosses‚Äù means, collectively, any and all claims, liabilities, damages, losses, costs, expenses, including reasonable fees and disbursements of counsel and any consultants or experts and expenses of investigation, obligations, liens, assessments, judgments, fines and penalties imposed upon or incurred by an Indemnified Party.\n",
      "5\n",
      "‚ÄúMaterial Third Party Supplier‚Äù means a Third Party Supplier that provides materials used in the cGMP manufacture, testing or processing of cGMP Intermediate or API.\n",
      "‚Äú[***] Forecast‚Äù has the meaning provided in Section 2.4(b) of this Agreement.\n",
      "‚ÄúNonconformity‚Äù has the meaning provided in Section 6.4(a) of this Agreement.\n",
      "‚ÄúNonconforming API‚Äù means API that is subject to a Nonconformity.\n",
      "‚ÄúParty‚Äù and ‚ÄúParties‚Äù have the meanings given such terms, respectively, in the preamble of this Agreement.\n",
      "‚ÄúPerson‚Äù means any individual, corporation, company, partnership, trust, incorporated or unincorporated association, joint venture or other entity of any kind.\n",
      "‚ÄúPre-Approval Inspection‚Äù means an inspection of manufacturing operations, records and facilities conducted prior to approval of a new product by the FDA or by any other applicable Governmental Body having jurisdiction to approve the Facility as a cGMP facility for the manufacture of the API.\n",
      "‚ÄúProduct‚Äù means (a) ‚Äôs AMR101 product, and (b) any finished pharmaceutical product of  that incorporates the API supplied by  pursuant to this Agreement.\n",
      "‚ÄúPurchase Orders‚Äù has the meaning provided in Section 2.5 of this Agreement.\n",
      "‚ÄúQuality Agreement‚Äù means the agreement identified in Section 5.6 of this Agreement. ‚ÄúSecondary Supplier‚Äù has the meaning set forth in Section 2.5 of this Agreement.\n",
      "‚ÄúSecond Expansion‚Äù has the meaning provided in Section 4.3 of this Agreement.\n",
      "‚ÄúShipment Date‚Äù means the date specified by  in a Purchase Order that  shall ship the API in accordance with this Agreement.\n",
      "‚ÄúSubcontractor‚Äù means any Third Party that performs any of the activities with respect to the manufacture and supply of API under this Agreement on ‚Äôs behalf.\n",
      "‚ÄúTerm‚Äù has the meaning provided in Section 15.1 of this Agreement.\n",
      "‚ÄúThird Party‚Äù means any Person other than the Parties or their respective Affiliates.\n",
      "‚ÄúThird Party Materials‚Äù means (a) all raw materials, components, work-in-process and other ingredients required to manufacture the API, and (b) all packaging materials used in the manufacture, storage and shipment of the API.\n",
      "‚ÄúThird Party Supplier‚Äù means any Third Party that provides to  any Third Party Materials for any API produced under this Agreement.\n",
      "‚ÄúValidation‚Äù means a procedure for establishing documentation evidence that a specific system or facility is constructed and operates according to a predetermined set of specifications, protocols and guidelines.\n",
      "‚ÄúValidation Batch‚Äù has the meaning provided in Section 4.2 of this Agreement.\n",
      "6\n",
      "Article II\n",
      "Sale and Purchase of API\n",
      "2.1 General.\n",
      "(a) Development and Process Validation Plan. Subject to the terms and conditions of this Agreement,  agrees to conduct the Development and Process Validation Plan.\n",
      "(b) Manufacture of API. Subject to the terms and conditions of this Agreement,  agrees to manufacture API at the Facility for sale to .  may not manufacture API at locations other than the Facility without the prior written Consent of , such Consent not to be unreasonably withheld or delayed and as provided in the Quality Agreement. For the avoidance of doubt, the Parties agree that this Agreement does not obligate  to purchase all of its requirements of the API from , nor does it obligate  to purchase any particular volumes of API from  except as expressly set forth herein, nor does it obligate  to sell the API exclusively to  except as set forth in Section 2.3.  retains the right to engage or appoint additional suppliers and contract manufacturers of the API from time to time in its sole discretion and  retains the right to supply API to Third Party customers and to appoint Third Party distributors of the API from time to time in its sole discretion.\n",
      "2.2 Minimum Purchase Requirement and Supply of Development Quantities.  agrees to purchase from , and  agrees to supply to , (a) no more than [***] batches (each batch shall be in a quantity of [***], which shall include the quantity of the Validation Batches) of API upon the Validation of the Initial Manufacturing Process pursuant to the Development and Process Validation Plan, (b) [***] of API annually (or such prorated amount in the case of a partial year) following [***], and (c) [***] of API annually (or such prorated amount in the case of a partial year) following [***]. From time to time during ‚Äôs expansion activities, as may be reasonably necessary, and upon no less than ten (10) days‚Äô advance written notice,  shall deliver to  (at no cost) quantities of API not to exceed two (2) kilograms for  to evaluate and test.\n",
      "2.3 Limited Exclusivity; Capacity Allocation.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 3 (Length: 9760 characters):\n",
      "(b) Manufacture of API. Subject to the terms and conditions of this Agreement,  agrees to manufacture API at the Facility for sale to .  may not manufacture API at locations other than the Facility without the prior written Consent of , such Consent not to be unreasonably withheld or delayed and as provided in the Quality Agreement. For the avoidance of doubt, the Parties agree that this Agreement does not obligate  to purchase all of its requirements of the API from , nor does it obligate  to purchase any particular volumes of API from  except as expressly set forth herein, nor does it obligate  to sell the API exclusively to  except as set forth in Section 2.3.  retains the right to engage or appoint additional suppliers and contract manufacturers of the API from time to time in its sole discretion and  retains the right to supply API to Third Party customers and to appoint Third Party distributors of the API from time to time in its sole discretion.\n",
      "2.2 Minimum Purchase Requirement and Supply of Development Quantities.  agrees to purchase from , and  agrees to supply to , (a) no more than [***] batches (each batch shall be in a quantity of [***], which shall include the quantity of the Validation Batches) of API upon the Validation of the Initial Manufacturing Process pursuant to the Development and Process Validation Plan, (b) [***] of API annually (or such prorated amount in the case of a partial year) following [***], and (c) [***] of API annually (or such prorated amount in the case of a partial year) following [***]. From time to time during ‚Äôs expansion activities, as may be reasonably necessary, and upon no less than ten (10) days‚Äô advance written notice,  shall deliver to  (at no cost) quantities of API not to exceed two (2) kilograms for  to evaluate and test.\n",
      "2.3 Limited Exclusivity; Capacity Allocation.\n",
      "(a) During the Term (i)  shall not export, sell or distribute a [***] product incorporating Compound having a purity level greater than [***] that [***] for use in [***], (ii)  shall not export, sell or distribute Compound having a purity level greater than [***] to any Third Party that exports, sells or distributes a [***] product incorporating the Compound that [***] for use in [***], (iii)  shall not export, sell or distribute a [***] product incorporating Compound having a purity level greater than [***] for use in the [***], and (iv)  shall not export, sell or distribute Compound having a purity level greater than [***] to any Third Party for use in a [***] product in the [***]; provided, however, for the avoidance of doubt, the prohibitions in this Section 2.3 shall not apply to (A) sales of a generic form of [***], (B) [***] in ‚Äôs export, sale or distribution of Compound having a purity level greater than [***] to any Third Party that exports, sells or distributes a [***] product incorporating the Compound that [***] for use in the [***]; and (C) [***] in ‚Äôs export, sale or distribution of Compound having a purity level greater [***] to any Third Party for use in a [***] product in the [***].\n",
      "(b) Except as set forth in Section 2.3(a), above,  shall be entitled to maximize its capacity utilization of the Facility by manufacturing products for Third Parties or itself in addition to the API; provided, however, that if  is expected to be unable to supply all of the API forecast by  and all of the needs of such other Persons,  shall allocate such Facility capacity on a first priority basis to .\n",
      "7\n",
      "(c) This Section 2.3 shall expire in the event  does not order the minimum annual quantities set forth in Section 2.2(b) or (c), as applicable, in any Calendar Year. For purposes of determining the quantities ordered by  in a Calendar Year, (i) all quantities subject to Purchase Orders placed in such Calendar Year, (ii) all quantities of Validation Batches of API purchased pursuant to Section 5.4(a) in such Calendar Year, (iii) all quantities ordered from a Secondary Supplier due to ‚Äôs failure to supply API hereunder in such Calendar Year, and (iv) all quantities ordered from a Secondary Supplier due to a Force Majeure Event in such Calendar Year shall be included in such determination.\n",
      "2.4 Forecasts.\n",
      "(a) Not later than [***] following the Effective Date,  shall provide  with a [***], nonbinding forecast of the quantity of API  projects it may purchase from  beginning [***] prior to the anticipated commercial launch of the Product (the ‚ÄúCommercial Launch Forecast‚Äù).  shall submit an updated Commercial Launch Forecast (which shall also be nonbinding) within [***] after [***].\n",
      "(b) Not later than [***] after the [***],  shall, on a [***] basis, provide  with a [***] rolling forecast of the quantity  intends to order during each [***] (each such forecast referred to herein as a ‚Äú[***] Forecast‚Äù). The forecast amount for the first [***] of the [***] Forecast shall be binding on both Parties. The forecast amounts for the remaining [***] of each [***] Forecast, i.e., [***], shall be non-binding forecast amounts.  shall not be obligated to supply API in excess of the binding forecast amounts contained in the [***] Forecasts. Notwithstanding anything in this Agreement to the contrary, (i) in no event shall  be obligated to manufacture during a [***] prior to the Expansion more than its then-existing [***] capacity divided by [***] and (ii) in no event shall  be obligated to manufacture in [***] following the Expansion more than ‚Äôs [***] divided by [***].\n",
      "2.5 Purchase Orders. From time to time,  shall deliver to  one (1) or more purchase orders (‚ÄúPurchase Orders‚Äù) for the aggregate API volumes in each binding portion of a [***] Forecast. Each Purchase Order shall specify the volumes of API ordered, the Shipment Date and the destination for delivery of the API. The Purchase Orders may be delivered electronically or by other means to such location as  shall designate.  shall deliver such API to ‚Äôs carrier on the Shipment Date specified by ; provided, however, that the Shipment Date is no less than [***] after the date of the submission of the Purchase Order. In the event that  shall not be able to deliver API to ‚Äôs carrier by the Shipment Date specified in a Purchase Order,  shall notify  promptly in writing upon discovery of its inability to comply with the terms of this Section 2.5; provided, however, that such notification shall not relieve  of any liability for failure to deliver API to ‚Äôs carrier on such Shipment Date.\n",
      "If  fails to meet the Purchase Order or any portion thereof on or before the applicable Shipment Date, in addition to other remedies that may be available to  under the Legal Requirements,  may purchase the shortage of such API from Third Parties and  shall pay to  the difference in price of such API purchased from a Third Party (a ‚ÄúSecondary Supplier‚Äù) and the API Price for the API shortage; provided, however, that in no event shall such payment exceed an amount equal to the volume of shortage times [***] of the then applicable API Price that  is charging to  for API.\n",
      "8\n",
      "If  fails to order API in the amount specified in the binding portion of the [***] Forecast, in addition to other remedies that may be available to  under the Legal Requirements,  shall pay to  [***] of the then current API Price that  is charging to  for API for the volume of API under the binding portion of the [***] Forecast less the actual amount ordered by .\n",
      "If  fails to purchase the relevant minimum yearly purchase requirement as set forth above, in addition to other remedies that may be available to  under the Legal Requirements,  shall pay to  [***] of the then current API Price that  is charging to  for API for the relevant minimum yearly purchase requirement as set forth above less the actual amount purchased by  in the relevant year.\n",
      "2.6 Accommodations. From time to time,  may deliver to  a Purchase Order for API volumes in excess of those specified in any binding portion of a [***] Forecast.  shall notify  in writing as to whether  is able to supply the excess volume of API, but shall not otherwise be obligated to supply the excess volume of API.\n",
      "2.7 Meetings. Unless otherwise mutually agreed, the Parties shall meet or otherwise communicate no less than [***] to discuss the progression of the Development and Process Validation Plan, the Expansion, the Second Expansion, the forecasts delivered by  pursuant to this Agreement and other matters relevant to the supply of API hereunder. The Parties shall use commercially reasonable efforts to accommodate technical meetings requested by both Parties.\n",
      "Article III\n",
      "Financial Matters\n",
      "3.1 API Price.\n",
      "(a) API Price. Schedule 3.1 to this Agreement sets forth the price for API (the ‚ÄúAPI Price‚Äù) based on (i) the aggregate [***] represented by Purchase Orders in a Calendar Year (such aggregate quantities and associated pricing are delineated in Tier 1 of Matrix I and Tier 1, 2, 3, 4, 5 and 6 of Matrix II of Schedule 3.1) and (ii) timely completion of the Expansion and/or the Second Expansion (the associated pricing are delineated in Matrices I and II of Schedule 3.1). In the event  expands the Facility beyond the Second Expansion (‚ÄúAdditional Expansions‚Äù), the Parties will negotiate in good faith the price of the API supplied in excess of [***] per year based on a tiered pricing scheme that recognizes relevant investments, the efficiencies in the manufacturing processes of the expanded Facility and any change in ‚Äôs cost of manufacturing API.\n",
      "(b) Calculation. Following ‚Äôs first delivery of a [***] Forecast in each [***] during the Term of this Agreement,  shall estimate:\n",
      "(i) The aggregate forecast orders for such [***] to estimate whether pricing Tier 1 of Matrix I or Tier 1, 2, 3, 4, 5 or 6 of Matrix II (as set forth in Schedule 3.1) is applicable.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 4 (Length: 9843 characters):\n",
      "2.6 Accommodations. From time to time,  may deliver to  a Purchase Order for API volumes in excess of those specified in any binding portion of a [***] Forecast.  shall notify  in writing as to whether  is able to supply the excess volume of API, but shall not otherwise be obligated to supply the excess volume of API.\n",
      "2.7 Meetings. Unless otherwise mutually agreed, the Parties shall meet or otherwise communicate no less than [***] to discuss the progression of the Development and Process Validation Plan, the Expansion, the Second Expansion, the forecasts delivered by  pursuant to this Agreement and other matters relevant to the supply of API hereunder. The Parties shall use commercially reasonable efforts to accommodate technical meetings requested by both Parties.\n",
      "Article III\n",
      "Financial Matters\n",
      "3.1 API Price.\n",
      "(a) API Price. Schedule 3.1 to this Agreement sets forth the price for API (the ‚ÄúAPI Price‚Äù) based on (i) the aggregate [***] represented by Purchase Orders in a Calendar Year (such aggregate quantities and associated pricing are delineated in Tier 1 of Matrix I and Tier 1, 2, 3, 4, 5 and 6 of Matrix II of Schedule 3.1) and (ii) timely completion of the Expansion and/or the Second Expansion (the associated pricing are delineated in Matrices I and II of Schedule 3.1). In the event  expands the Facility beyond the Second Expansion (‚ÄúAdditional Expansions‚Äù), the Parties will negotiate in good faith the price of the API supplied in excess of [***] per year based on a tiered pricing scheme that recognizes relevant investments, the efficiencies in the manufacturing processes of the expanded Facility and any change in ‚Äôs cost of manufacturing API.\n",
      "(b) Calculation. Following ‚Äôs first delivery of a [***] Forecast in each [***] during the Term of this Agreement,  shall estimate:\n",
      "(i) The aggregate forecast orders for such [***] to estimate whether pricing Tier 1 of Matrix I or Tier 1, 2, 3, 4, 5 or 6 of Matrix II (as set forth in Schedule 3.1) is applicable.\n",
      "(ii) The aggregate [***] subject to the pricing set forth in Schedule 3.1. Up to [***] shall be subject to Matrix I pricing (as set forth in Schedule 3.1) once the Expansion is completed. In the event  invests in the Second Expansion, up to [***] shall be subject to Column A of Matrix II pricing (as set forth in Schedule 3.1) once the Second Expansion is completed. In the event  does not invest in the\n",
      "9\n",
      "Second Expansion, up to [***] shall be subject to Column B of Matrix II pricing (as set forth in Schedule 3.1) once the Second Expansion is completed. All other amounts shall be subject to subsequent negotiation between the Parties. For the avoidance of doubt, the API Prices listed in Schedule 3.1 for quantities in excess of [***] are target prices and are subject to good faith negotiations. Furthermore, in the event the price for Column B of Tier 1 or Tier 2 of Matrix II (currently marked as ‚ÄúTBD‚Äù) becomes necessary,  and  shall negotiate in good faith to reach an agreement on such prices.\n",
      "Based on such estimates in (i) and (ii) above,  shall advise  in writing, and provide  supporting documentation and calculations, of the weighted average API Price under Schedule 3.1.  shall thereafter have the right to review ‚Äôs calculation of the weighted average API Price and consult with  with respect thereto. In the event  does not agree with ‚Äôs calculation of the weighted average API Price, the Parties shall use their respective commercially reasonable efforts to agree to the proper calculation of the weighted average API Price. In the event the Parties are unable to agree within [***], the dispute shall be resolved as provided in Section 16.5. The API Price determined by this subsection (b) shall be the API Price invoiced and paid for Purchase Orders submitted during such [***] (and retroactively applied to any Purchase Orders delivered in such [***] prior to the determination of such API Price). Such API Price, however, shall be subject to a year-end retroactive adjustment pursuant to subsection (c) below.\n",
      "(c) Annual Adjustment. Within [***] after each December 31 during the Term of this Agreement and within [***] following the termination of this Agreement,  will determine:\n",
      "(i) The aggregate [***] represented by Purchase Orders in the prior Calendar Year to determine whether pricing Tier 1 of Matrix I or Tier 1, 2, 3, 4, 5 or 6 of Matrix II (as set forth in Schedule 3.1) is applicable.  shall include in such determination the aggregate amount of API, if any, for which  submits a purchase order to a Secondary Supplier in such Calendar Year due to (A) ‚Äôs failure to supply API hereunder and/or (B) a Force Majeure Event. Any Validation Batches of API purchased pursuant to Section 5.4 in such Calendar Year shall also be included. In the case of a partial year, the aggregate [***] represented by Purchase Orders in such prior partial year shall be annualized in such determination.\n",
      "(ii) The aggregate [***] for the pricing is set forth in Schedule 3.1 based on (A) timely completion of the Expansion and ‚Äôs investment in the Second Expansion and (B) the limits set forth in Section 3.1(b).\n",
      "(iii) The aggregate amounts paid to  under Purchase Orders issued in the prior Calendar Year.\n",
      "Based on such determinations set forth in (i), (ii) and (iii) above,  shall advise  in writing, and provide supporting documentation and calculations, of (A) the weighted average API Price for such prior Calendar Year, (B) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year, and (C) the difference between (1) the aggregate amounts paid to  under Purchase Orders issued in the prior Calendar Year and (2) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year.  shall thereafter have the right to review ‚Äôs calculations and consult with  with respect thereto. In the event  does not agree with ‚Äôs calculations, the Parties shall use their respective commercially reasonable efforts to\n",
      "10\n",
      "agree to the proper calculations. In the event the Parties are unable to agree within thirty (30) days, the dispute shall be resolved as provided in Section 16.5. The API Price for such prior Calendar Year, the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year, and the difference between (x) the aggregate amounts paid to  under Purchase Orders issued in the prior Calendar Year and (y) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year determined by this Subsection (c) shall be the final determinations thereof. In the event that (x) the aggregate amounts paid to  under Purchase Orders issued in the prior Calendar Year are greater than (y) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year,  shall pay  the difference within [***] of the final determination thereof. In the event that (x) the aggregate amounts paid to  under Purchase Orders issued in the prior Calendar Year are less than (y) the aggregate purchase price for all API subject to all Purchase Orders issued in the prior Calendar Year,  shall pay  the difference within [***] of the final determination thereof. In addition, the final API Price for the prior Calendar Year determined by this Subsection (c) shall be the price for API subject to Purchase Orders placed in the prior Calendar Year but not invoiced prior to final determination of the API Price, and  shall invoice such amounts accordingly.\n",
      "(d) Packaging. The Parties hereby agree that  shall be responsible for up to [***] of the cost of each packaging container used for transportation of the API to . The rest of the cost of each such packaging container shall be borne by .\n",
      "(e) Price Adjustment. Effective from the [***] anniversary date of the Effective Supply Date,  shall be entitled to make an adjustment to the API Prices listed in Schedule 3.1 in accordance with the methodology described in Schedule 3.1(e) by giving  written notice of such new API Prices at least [***] prior to the relevant anniversary of the Effective Supply Date.  may request in writing that  make such an API Price adjustment, if applicable, by providing such written notice at least [***] prior to the relevant anniversary of the Effective Supply Date. If so requested by ,  shall provide  written notice of such new API Prices, if applicable, at least [***] prior to the relevant anniversary of the Effective Supply Date. Within [***] from the date of receipt of written notice of any API Price change,  may request  to provide its API Price adjustment records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by  are correct and in accordance with the methodology described in Schedule 3.1(e). Such certification shall be made in writing on the auditing firm‚Äôs letterhead and delivered to  at least [***] prior to the relevant anniversary of the Effective Supply Date. No increase in the API Prices may occur until the audit has been completed and the price adjustment has been certified as described above. In the event the audit reveals that the increase is appropriate,  shall bear the cost of the audit, and shall pay the increased API Prices for API in purchase orders from the relevant anniversary of the Effective Supply Date. In the event the audit reveals that the increase is not appropriate, then  shall bear the cost of the audit and the API Prices of API may not increase. The increase of the API Prices of API shall be deemed accepted by  if  fails to make a timely request for an audit as described above or the requested audit is not completed at least [***] prior to the relevant anniversary of the Effective Supply Date.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 5 (Length: 9799 characters):\n",
      "3.2 Commercial Invoices.  may invoice  for API on or before the Shipment Date of such API to  or its designee pursuant to Section 3.5(a). All invoices shall be commercial invoices and shall include the following: (a) ‚ÄòCommercial Invoice‚Äô written on the top of the document, (b) the date of the invoice, (c) the number of the Purchase Order, (d) an invoice number, (e) the quantity of API, (f) the total amount being invoiced, and (g) a reference to this Agreement, and shall be submitted to:\n",
      ".\n",
      "11\n",
      "3.3 Payment. Payments for API invoiced consistent with Section 3.2 above shall be due [***] from the date of shipment, subject in each case to ‚Äôs right to dispute invoice amounts and/or delay the payment of invoiced amounts disputed by  in good faith, including, without limitation, the rights set forth in Article VI.\n",
      "3.4 Payment Denominations. The API Price, all invoiced amounts and all payments to be made under this Agreement shall be in [***].\n",
      "3.5 Shipment; Title; Transport.\n",
      "(a) General. All API shall be shipped [***] (as defined in INCOTERMS¬Æ 2010) [***]. Subject to Section 3.1(d),  shall package the API for shipment (including but not limited to containers, packaging, container closure systems and labeling) in accordance with the API Specifications, ‚Äôs reasonable instructions and its customary practices therefor. In the event of any conflict between ‚Äôs packaging instructions and ‚Äôs customary practices, the Parties shall endeavor in good faith to resolve such conflict as quickly as practicable.  shall include the following with each shipment of the API: (i) the Purchase Order number; (ii) the lot and batch numbers; (iii) the quantity of the API; (iv) the Certificates, as applicable; and (v) such customs and other documentation as is necessary or appropriate.  shall ship API to the destination designated by  within [***] of the manufacture date for Purchase Orders of quantities up to [***] and [***] of the manufacture date for Purchase Orders of quantities exceeding [***].\n",
      "(b) Title/Risk of Loss. Title to and risk of loss for any API shall pass from  to  when such API is [***]; provided, however, that nothing in this Article III shall in any manner limit ‚Äôs rights under Article VI. If API is rejected by  after delivery under this Agreement, and such API is to be returned to , then title to and risk of loss for such rejected API shall pass from  to  when such API is [***]. All returned API shall be shipped [***] (as defined in INCOTERMS 2010)\n",
      "¬Æ\n",
      "[***].\n",
      "(c) Single Order. To the extent reasonably possible, API which is purchased in a single order shall be delivered by  in a single shipment, unless  directs that such API should be delivered to more than one location.\n",
      "(d) Shelf Life. The API shall have a minimum shelf life of [***] as of the applicable date of manufacture. The minimum shelf life set forth in the immediately preceding sentence is based on existing stability data. In the event future stability data justifies a longer shelf life, the Parties agree to discuss in good faith an extended minimum shelf life as of the applicable date of manufacture.\n",
      "12\n",
      "3.6 Taxes.\n",
      "(a)  shall pay and otherwise be responsible for all applicable sales, VAT, goods, services, transfer and similar taxes in connection with the supply of API pursuant to this Agreement, excluding any income tax or taxes levied with respect to gross receipts, payable by  under the Legal Requirements with respect to amounts payable under this Agreement.\n",
      "(b) Any tax that one Party is required to withhold and pay on behalf of the other Party with respect to amounts payable under this Agreement shall be deducted from said amounts prior to payment to the other Party; provided, however, that, in regard to any tax so deducted, the Party making the withholding shall give or cause to be given to the other Party such assistance as may reasonably be necessary to enable that other Party to claim exemption therefrom or credit therefor and in each case shall furnish the Party on whose behalf amounts were withheld proper evidence of the taxes paid on its behalf. Each Party shall comply with reasonable requests of the other Party to take any proper actions that may minimize any withholding obligation.\n",
      "Article IV\n",
      "Capacity, Expansion\n",
      "4.1 Capacity. Within [***] after the Effective Date,  shall expand the Facility‚Äôs capacity to supply annually [***] of API (with design capacity of [***] annually) as further detailed in Schedule 4.1 (the ‚ÄúExpansion‚Äù). In the event that the Expansion is not complete (as described in Section 4.2) within such [***] period,  shall provide  a written request to extend such period accompanied with a summary of the progression of the Expansion and steps needed to complete the Expansion. Upon submission of such request,  shall have an additional [***] period to complete the Expansion. Following completion of the Expansion,  shall maintain at all times during the Term the capacity to supply  no less than [***] of API each Calendar Year (‚Äú‚Äôs Initial Minimum Capacity‚Äù). ‚Äôs capacity as further expanded in accordance with this Agreement, together with ‚Äôs Initial Minimum Capacity, shall be referred to herein as ‚Äú‚Äôs Minimum Capacity.‚Äù\n",
      "4.2 Completion. The Expansion will be deemed to be completed for purposes of this Agreement if all of the requirements set forth in Schedule 4.1 have been satisfied and  has manufactured [***] successful, consecutive batches (each batch shall be in a quantity of [***]) of API (each a ‚ÄúValidation Batch‚Äù) in the expanded Facility that satisfy the requirements of this Agreement.\n",
      "4.3 Second Expansion. Upon [***],  will initiate a second expansion of the Facility to expand the capacity to [***] of API (with a design capacity of [***]) each Calendar Year (the ‚ÄúSecond Expansion‚Äù), provided, however, the Parties shall mutually agree on the timing and schedule of such expansion activity. The summary plan for the Second Expansion is set forth in Schedule 4.5, and  shall submit a detailed development and validation plan for the Second Expansion within thirty (30) days of the later to occur of [***] and [***]. The Second Expansion will be deemed completed for purposes of this Agreement if all the requirements set forth in Schedule 4.5 have been satisfied and  has manufactured [***] successful, consecutive Validation Batches in the expanded Facility that satisfy the requirements of this Agreement.\n",
      "Article V\n",
      "Manufacture of API\n",
      "5.1 General.  shall manufacture, test, package, store, handle, label, release and ship all API in accordance with the applicable Drug Applications, API Specifications, cGMPs, Legal Requirements, this Agreement and the Quality Agreement.\n",
      "13\n",
      "5.2 API Specification Changes.\n",
      "(a)  Requested Changes. During the Term, except as set forth in Section 5.2(c),  shall not be entitled to change the API Specifications related to ‚Äôs performance of its obligations hereunder related to API unless it receives the Consent of , which Consent shall not be unreasonably withheld or delayed. If  requests, and  approves, a discretionary change to the API Specifications,  shall make all revisions to the API Specifications requested by .  retains the right and responsibility for final approval of the API Specifications.  shall pay  all documented reasonable amounts incurred in implementing a change to the API Specifications requested by  under this Section 5.2(a). For all changes to the API Specifications requested by  pursuant to this Section 5.2,  shall, in its discretion, following consultation with , if reasonably practicable, either (i) perform, or arrange for the performance of, all development work in connection therewith or (ii) have  perform such development work at the Facility at ‚Äôs expense. For the avoidance of doubt, Section 5.2(a)(i) does not give  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).  agrees to use commercially reasonable efforts to minimize its costs associated with any API Specification change. At the request of ,  shall evaluate the estimated costs and timing of potential revisions to the API Specifications.\n",
      "(b)  Changes.  shall not make any revisions to the API Specifications, the manufacturing process or Material Third Party Suppliers, without prior written Consent of , which Consent shall not be unreasonably withheld or delayed. If the Parties implement a change in the API Specifications or the manufacturing process under this Section 5.2, they shall negotiate any changes in any affected Purchase Order to provide reasonable accommodation for changed circumstances. The costs of revisions requested by  under this Section 5.2(b) shall be borne by  without any increase in the API Price.\n",
      "(c) Changes Mandated by Legal Requirements. Notwithstanding anything in subsections (a) and (b) of this Section 5.2 to the contrary, (i)  shall implement all changes to the API Specifications intended to maintain compliance with Legal Requirements, to bring the API Specifications into compliance with Legal Requirements or to accommodate the demands or requests of any Governmental Body; (ii) unless such changes are generally applicable to the Facility or ‚Äôs manufacture of other products, the Parties shall bear equally the expense of any of such changes; and (iii) if the changes are generally applicable to the Facility or ‚Äôs manufacture of other products,  shall bear the expense of any of such changes. Notwithstanding the foregoing, if changes to Legal Requirements generally affecting manufacturers of drugs containing the Compound significantly increase the cost for  to supply API hereunder, then the Parties agree to negotiate in good faith any appropriate adjustments to this Agreement.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 6 (Length: 9885 characters):\n",
      "(b)  Changes.  shall not make any revisions to the API Specifications, the manufacturing process or Material Third Party Suppliers, without prior written Consent of , which Consent shall not be unreasonably withheld or delayed. If the Parties implement a change in the API Specifications or the manufacturing process under this Section 5.2, they shall negotiate any changes in any affected Purchase Order to provide reasonable accommodation for changed circumstances. The costs of revisions requested by  under this Section 5.2(b) shall be borne by  without any increase in the API Price.\n",
      "(c) Changes Mandated by Legal Requirements. Notwithstanding anything in subsections (a) and (b) of this Section 5.2 to the contrary, (i)  shall implement all changes to the API Specifications intended to maintain compliance with Legal Requirements, to bring the API Specifications into compliance with Legal Requirements or to accommodate the demands or requests of any Governmental Body; (ii) unless such changes are generally applicable to the Facility or ‚Äôs manufacture of other products, the Parties shall bear equally the expense of any of such changes; and (iii) if the changes are generally applicable to the Facility or ‚Äôs manufacture of other products,  shall bear the expense of any of such changes. Notwithstanding the foregoing, if changes to Legal Requirements generally affecting manufacturers of drugs containing the Compound significantly increase the cost for  to supply API hereunder, then the Parties agree to negotiate in good faith any appropriate adjustments to this Agreement.\n",
      "5.3 Storage and Handling Obligations. When storing and handling API, Third Party Materials, Nonconforming API or API-derived wastes,  shall comply with, and shall maintain all storage facilities in compliance with, the API Specifications, cGMPs, Legal Requirements and the Quality Agreement.\n",
      "14\n",
      "5.4 Validations and Stability Studies.\n",
      "(a) Initial Manufacturing Process Validation.  shall as soon as practicable complete the Validation of the manufacturing process for the API in connection with the Expansion (the ‚ÄúInitial Manufacturing Process‚Äù) in accordance with activities set forth in the Development and Process Validation Plan at no additional cost to . The Development and Process Validation Plan shall, among other things, include activities necessary to establish the Facility as a cGMP facility, a validation plan and appropriate protocols. Without limiting the foregoing,  will provide process progress reports to  no less frequently than [***], which reports shall include, without limitation, reasonable details related to construction, equipment installation and process implementation, subject to redaction of any  Confidential Information. Promptly following completion of Validation of the Initial Manufacturing Process,  shall deliver a final report to  that includes a summary of regulatory data and documentation respecting the manufacture of the API, without disclosing any confidential process information, all in compliance with applicable FDA guidelines and any other applicable Legal Requirements but subject to redaction of any  Confidential Information.\n",
      "(i) The Parties shall participate in project teleconferences with each other as reasonably requested by the other Party to successfully complete the Validation of the Initial Manufacturing Process. During development and Validation of the Initial Manufacturing Process,  will accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by . Without limiting the foregoing, during process development and in support of API process characterization and Validation activities,  will be permitted to conduct reviews of the Facility and the pertinent records maintained by , subject to restriction on access to all  Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon ‚Äôs request and with reasonable notice to permit  to support such technical reviews.\n",
      "(ii) In conjunction with the foregoing Validation pursuant to the Development and Process Validation Plan,  will produce process Validation Batches.  shall be required to purchase Validation Batches of API provided that they comply with the API Specifications and Validation acceptance criteria and are otherwise in compliance with the terms of this Agreement. The establishment and Validation of the Initial Manufacturing Process shall be deemed to be complete upon the manufacture of such [***] successful, consecutive Validation Batches that comply with the API Specifications and Validation criteria and are otherwise in compliance with the terms of this Agreement and the Development and Process Validation Plan.\n",
      "(iii) With the prior written consent of the other Party, a Party may engage in teleconferences, in person meetings, Facility reviews, quality assurance audits, records reviews and other activities under this Agreement through its (or its Affiliates‚Äô) employees or consultants with a bona fide need to know, but only to the extent necessary for the Party to exercise its rights and discharge its obligations under this Agreement, provided that (A) each such employee and consultant has executed a written confidentiality agreement containing use and disclosure restrictions at least as protective as those set forth in Article XIII, and (B) any  consultant shall be reasonably acceptable to  (such persons, ‚ÄúApproved Representatives‚Äù).\n",
      "(b) Process Validation for Improved Manufacturing Processes. The Parties acknowledge that  or  may from time to time desire to pursue strategies and\n",
      "15\n",
      "efficiencies for improving the manufacturing processes for the API. Each Party agrees to reasonably evaluate and discuss any such suggestions for improvements that the other Party reasonably believes in good faith may result in significant cost or time savings in the manufacturing process.\n",
      "(c) General. Without limiting the foregoing,  shall perform at no additional cost to  on an on-going basis all Validations and stability studies required by the applicable Drug Applications, the API Specifications, cGMPs or Legal Requirements in connection with the regular course of manufacturing the API for commercial supply.\n",
      "(d) Duties. In performing its duties under this Section 5.4,  shall perform the following tasks, consistent with the Quality Agreement:\n",
      "(i) implement and operate an ICH complaint stability program;\n",
      "(ii) notify ‚Äôs head of regulatory affairs, or his or her designee, promptly, but within not more than [***], if any batch of API fails any stability tests; and\n",
      "(iii) report to ‚Äôs head of regulatory affairs, or his or her designee, promptly, but within not more than [***], any Nonconformity, significant atypical results, deviations or adverse trends exhibited during final release or stability testing.\n",
      "(e) Manufacturing Process Review. At either Party‚Äôs reasonable request, the Parties shall promptly meet, in person or telephonically, for the purpose of reviewing such matters related to manufacturing of the API as may be specified by a Party, including discussing strategies for improving the API manufacturing processes.\n",
      "(f) Confidential Information. Notwithstanding anything to the contrary contained in this Agreement,  may redact or limit from any deliveries of or access to data, reports or any other information to  any Third Party confidential information or  Confidential Information, at ‚Äôs sole discretion; provided, however, that  may not redact or limit any  Confidential Information that is reasonably necessary for  to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide the relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to  under this Section 5.4 is  Confidential Information and nothing in this Section 5.4 shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).\n",
      "5.5 Third Party Materials.\n",
      "(a) General.  shall be responsible for procuring, inspecting, testing and releasing adequate Third Party Materials that comply with cGMP and this Agreement as necessary to meet a Purchase Order for API.  shall perform all testing of Third Party Materials required by the applicable API Specifications, cGMP, Legal Requirements, this Agreement and the Quality Agreement.\n",
      "16\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "(c) Materials Certifications.  shall prepare or cause to be prepared by its Third Party Suppliers all certifications as to any Third Party Materials required by cGMPs or Legal Requirements.\n",
      "5.6 Quality Agreement. Within [***] following the Effective Date, the Parties shall enter into a quality agreement with such scope, terms and conditions as are customary within the pharmaceutical industry (such agreement, the ‚ÄúQuality Agreement‚Äù). In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement, the provisions of this Agreement shall govern.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 7 (Length: 9772 characters):\n",
      "5.5 Third Party Materials.\n",
      "(a) General.  shall be responsible for procuring, inspecting, testing and releasing adequate Third Party Materials that comply with cGMP and this Agreement as necessary to meet a Purchase Order for API.  shall perform all testing of Third Party Materials required by the applicable API Specifications, cGMP, Legal Requirements, this Agreement and the Quality Agreement.\n",
      "16\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "(c) Materials Certifications.  shall prepare or cause to be prepared by its Third Party Suppliers all certifications as to any Third Party Materials required by cGMPs or Legal Requirements.\n",
      "5.6 Quality Agreement. Within [***] following the Effective Date, the Parties shall enter into a quality agreement with such scope, terms and conditions as are customary within the pharmaceutical industry (such agreement, the ‚ÄúQuality Agreement‚Äù). In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement, the provisions of this Agreement shall govern.\n",
      "5.7 Compliance with Specifications, cGMPs and Legal Requirements.  shall be responsible for identifying and implementing, in accordance with its obligations under Section 5.1, any actions required to bring , Material Third Party Suppliers and Third Party Suppliers of starting materials for the Compound into compliance with API Specifications, cGMPs and Legal Requirements.  shall implement any such changes as soon as reasonably practicable (even if, in the case of cGMPs and Legal Requirements, a later effective date is specified), unless the required effective date for implementing such change falls after the effective date of any termination of this Agreement for which notice has been previously given.\n",
      "Article VI\n",
      "Testing and Quality Assurance\n",
      "6.1 Quality Assurance; Quality Control; Retains.\n",
      "(a)  shall implement and perform operating procedures and controls for sampling, ICH stability, release and other testing of Third Party Materials and API, and for Validation, documentation and release of the API and such other quality assurance and quality control procedures as required by the API Specifications, cGMPs, Legal Requirements, this Agreement and the Quality Agreement. Without limiting the foregoing,  shall establish an ICH stability program that collects no less than [***] data.  shall consult with  with respect to the details of the stability program, including analytical methods and stability container requirements.\n",
      "(b)  shall maintain for a period of time required by Legal Requirements, but in no event less than [***] after the expiration date of such API (i.e., a total of [***] from manufacture, subject to Section 3.5(d)), such quantities of the API from each batch of the API as are sufficient to conduct [***] full testings of the API in accordance with this Agreement.\n",
      "6.2 Testing of API. Prior to release of the API,  shall test the API in accordance with the Validation testing procedures described in the (a) applicable Drug Applications, (b) API Specifications, (c) cGMPs, (d) Legal Requirements, (e) Quality Agreement and (f) those procedures and in-plant quality control checks applicable to any products packaged by .  shall provide  with a copy of the records pertaining to\n",
      "such testing if reasonably requested, subject to redaction of any  Confidential Information. Additionally,  shall provide  with a Certificate of Analysis and/or any other certificate required by any applicable Governmental Body for release\n",
      "17\n",
      "of API (collectively, the ‚ÄúCertificates‚Äù) for each batch of API.  shall be under no obligation to accept any shipment of API without the accompanying Certificates. For the avoidance of doubt, all information provided to  under this Section 6.2 is  Confidential Information and nothing in this Section 6.2 shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).\n",
      "6.3  Holds, Rejections and Revocation of Acceptance.\n",
      "(a) General.  may test or cause to be tested the API delivered by  for a Nonconformity or reasonably suspected Nonconformity (as described below in Section 6.4). During such testing, at ‚Äôs reasonable request,  shall provide appropriate analytical reference standards for such testing to  or its designee. If  wishes to hold the API delivered to it by  for investigation of a Nonconformity or reasonably suspected Nonconformity,  shall so notify  stating the basis for the hold. ‚Äôs failure to comply with provisions of this Section 6.3 and 6.4, including timely notification of  of any Nonconformity, shall be deemed to be an irrevocable acceptance of any such relevant API by .\n",
      "(b) Independent Testing. If the Parties disagree as to whether API subject to hold, rejection or revocation of acceptance is subject to a Nonconformity, ‚Äôs and ‚Äôs respective designees shall confer to review samples and/or batch records, as appropriate, and  shall initiate a formal investigation. If the disagreement is not resolved within [***], then samples, batch records and other data relating to the batch in dispute shall promptly be submitted for testing and evaluation to a mutually acceptable independent Third Party (including a qualified testing laboratory to perform such testing using validated methods) mutually approved in writing by the Parties. The findings of such independent Third Party shall be binding on the Parties, absent manifest error. The expenses incurred by the Parties for the testing and evaluation by the Third Party shall be borne by  unless  has claimed that the API is subject to a Nonconformity, and the API in question is ultimately found not to be Nonconforming API.\n",
      "(c) Interim Replacement. During the pendency of any dispute concerning whether API is subject to a Nonconformity,  shall replace the shipment under dispute, at the request of , as soon as reasonably practicable.\n",
      "6.4 Nonconformity.\n",
      "(a) Nonconformity. If, within [***] following manufacture of a batch of API, either Party becomes aware or has a reasonable basis to believe that any batch or shipment of API may have a Nonconformity, at any time regardless of the status of ‚Äôs testing and quality assurance activities, such Party shall notify the other Party within [***] of becoming aware of a Nonconformity. ‚ÄúNonconformity‚Äù means a product characteristic that (i) results from ‚Äôs failure to manufacture, test, package, store, label, release or ship API in accordance with the API Specifications, cGMPs, ICH guidelines, Legal Requirements, this Agreement or the Quality Agreement, (ii) causes any API to fail to conform to the API Specifications, cGMPs or Legal Requirements, or (iii) constitutes an adulteration. In the event of a Nonconformity or reasonably suspected Nonconformity identified within [***] following manufacture of an affected batch of API, the Parties shall immediately (and in any case within [***]) conduct an investigation in accordance with Section 6.8 below and, until resolution of the investigation, handle the API as provided in Section 6.4(b) below.\n",
      "18\n",
      "(b) API That May Be Subject to a Nonconformity. Any batch or shipment of API that reasonably may be suspected to be subject to a Nonconformity shall be handled as follows and consistent with the Quality Agreement:\n",
      "(i) such API held in inventory at  shall be placed on ‚ÄúHold‚Äù and shall not be shipped to  or its designee, unless, upon completion of investigations pursuant to Section 6.8, such API is found to be not Nonconforming or it is directed otherwise by ;\n",
      "(ii) any such API shipped to  or its designee and held in stock by  or its designee shall maintain a ‚Äúhold‚Äù or ‚Äúrejected‚Äù status and shall not be released into approved inventory of  or its designee until the Parties have completed any investigations pursuant to Section 6.8; and\n",
      "(iii) payment for such API whether shipped or unshipped shall [***].\n",
      "Upon learning of a Nonconformity,  shall have the right to [***].\n",
      "(c) Remedy for Nonconforming API.\n",
      "(i) In the event that any quantity of API is found to be Nonconforming API prior to it being converted into Product and  notifies  of such Nonconformity within [***] following manufacture of such batch of API, then  may, at ‚Äôs discretion: (1) [***] and/or [***]; provided, however, that, with respect to the payment payable pursuant to [***], in no event shall such payment exceed an amount equal to [***] times [***] of [***]. For clarity, once API has been delivered by  under Section 3.5(a), it may not be reworked or reprocessed in the event it is found to be Nonconforming API.\n",
      "(ii) In the event that any Nonconforming API is held in inventory at , then  shall have such Nonconforming API destroyed.\n",
      "(iii) In connection with the destruction of API,  under Section 6.4(c)(i)(B)(3) or  under Section 6.4(c)(ii) shall be solely responsible for compliance with all Legal Requirements in connection with the destruction and shall be liable for any Losses resulting from such destruction, and the Party not directing the destruction of such API, as the case may be, may, if it so requests, (A) be present at such destruction, or (B) receive written documentation of such destruction.\n",
      "(iv)  shall use commercially reasonable efforts to perform any replacement of Nonconforming API on a priority basis and shall deliver such replacement API as soon as possible.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 8 (Length: 9273 characters):\n",
      "(ii) any such API shipped to  or its designee and held in stock by  or its designee shall maintain a ‚Äúhold‚Äù or ‚Äúrejected‚Äù status and shall not be released into approved inventory of  or its designee until the Parties have completed any investigations pursuant to Section 6.8; and\n",
      "(iii) payment for such API whether shipped or unshipped shall [***].\n",
      "Upon learning of a Nonconformity,  shall have the right to [***].\n",
      "(c) Remedy for Nonconforming API.\n",
      "(i) In the event that any quantity of API is found to be Nonconforming API prior to it being converted into Product and  notifies  of such Nonconformity within [***] following manufacture of such batch of API, then  may, at ‚Äôs discretion: (1) [***] and/or [***]; provided, however, that, with respect to the payment payable pursuant to [***], in no event shall such payment exceed an amount equal to [***] times [***] of [***]. For clarity, once API has been delivered by  under Section 3.5(a), it may not be reworked or reprocessed in the event it is found to be Nonconforming API.\n",
      "(ii) In the event that any Nonconforming API is held in inventory at , then  shall have such Nonconforming API destroyed.\n",
      "(iii) In connection with the destruction of API,  under Section 6.4(c)(i)(B)(3) or  under Section 6.4(c)(ii) shall be solely responsible for compliance with all Legal Requirements in connection with the destruction and shall be liable for any Losses resulting from such destruction, and the Party not directing the destruction of such API, as the case may be, may, if it so requests, (A) be present at such destruction, or (B) receive written documentation of such destruction.\n",
      "(iv)  shall use commercially reasonable efforts to perform any replacement of Nonconforming API on a priority basis and shall deliver such replacement API as soon as possible.\n",
      "(d) Credit/Reimbursement for Nonconforming API. In the event that  is obligated to  pursuant to Section 6.4(c),  shall, at ‚Äôs discretion, reimburse or credit  for (i) [***] and [***].  shall provide  with such documentation as  may reasonably request to confirm any of the foregoing charges, costs or expenses.  shall pay any unused credit amounts under this Section as of the expiration or termination of this Agreement to  within [***] after this Agreement is terminated.\n",
      "6.5 Quantitative Deficiencies. In the event  determines there is a quantitative deficiency in any shipment, with respect to the API volumes indicated on the applicable Purchase\n",
      "19\n",
      "Order(s),  shall properly document such deficiency and notify  thereof in writing. Upon such notice,  may, at its option: (a) pay only for actual quantities delivered, or (b) pay only for actual quantities delivered and require  to rectify any such deficiency by shipping the appropriate quantities of API to or as directed by , in which case  shall be obligated to pay for any such additional quantities pursuant to the terms and conditions of this Agreement.  shall use commercially reasonable efforts to rectify any such deficiency on a priority basis and deliver such additional quantities of API as soon as possible.\n",
      "6.6 Product Complaints Reports.\n",
      "(a) Received by . Any and all complaints of which  becomes aware relating to the Product shall promptly be forwarded to ‚Äôs head of regulatory affairs, or his or her designee, consistent with the Quality Agreement. Without limiting the foregoing,  shall forward any such complaint that might be associated with an Adverse Event (as defined below in Section 6.7) no later than [***] following its receipt.\n",
      "(b) Received by .  shall as soon as possible inform  of any and all complaints that  receives which implicate ‚Äôs manufacturing or other processes at the Facility. Notification shall be given by telephone, with a facsimile confirmation immediately following.\n",
      "6.7 Adverse Events.\n",
      "(a) Definition. For the purposes of this Agreement, ‚ÄúAdverse Event‚Äù shall mean any adverse event associated with the use of the Product in humans, whether or not considered drug-related, including but not limited to ‚Äúadverse event‚Äù as defined in ICH guidelines.\n",
      "(b)  Notice to .  shall notify ‚Äôs head of regulatory affairs, or any successor department specified by , as soon as possible, but no later than [***] following its receipt, of information concerning a possible Adverse Event. Notification shall be given by telephone, with a facsimile confirmation immediately following.  shall provide to  all of the information  has available concerning the Adverse Event and shall reasonably cooperate with any investigation conducted or directed by  as set forth in Section 6.8 below.\n",
      "(c)  Notice to . To the extent an Adverse Event of which  becomes aware implicates ‚Äôs manufacturing or other processes at the Facility,  shall inform  of such Adverse Event as soon as possible, but no later than [***] following its receipt of such information, and shall disclose to  any information  has regarding that Adverse Event which implicates ‚Äôs manufacturing or other processes at the Facility. Notification shall be given by telephone, with a facsimile confirmation immediately following.\n",
      "6.8 Investigations; ‚Äôs Obligations.\n",
      "(a) General. The Parties shall investigate all reports of Nonconformity, Product complaints, out-of trend analytical results, out-of-trend manufacturing yields, stability failure and Adverse Events. The Parties shall act promptly and shall cooperate fully in such investigations.\n",
      "20\n",
      "(b) Direction.\n",
      "(i) Investigations Related to Product or API Following Shipment.  shall have the sole right, in its discretion, to control and direct any or all aspects of an investigation conducted under this Section 6.8 with respect to matters related to API following shipment by  or with respect to the Product.  shall advise  from time to time throughout such investigation of ‚Äôs intentions regarding control and direction of such aspects of the investigation.  shall reasonably consult with  and shall reasonably afford  the opportunity to provide comments or suggestions regarding such investigation, which  agrees to consider in good faith.\n",
      "(ii) Investigations Related to API Prior to Shipment.  shall have the sole right, in its discretion, to control and direct any or all aspects of an investigation conducted under this Section 6.8 to the extent related to API prior to its shipment by .  shall advise  from time to time throughout such investigation of ‚Äôs intentions regarding control and direction of such aspects of the investigation.  shall reasonably consult with  and shall reasonably afford  the opportunity to provide comments or suggestions regarding such investigation, which  agrees to consider in good faith.\n",
      "(iii) Mutual Assistance. Upon written request by a Party in connection with an investigation, the other Party shall provide all reasonably requested testing results, assistance and information to the requesting Party in connection with an investigation of any Nonconformity, Product complaint or Adverse Event, including chemical/microbial analysis of complaint samples (if available), analysis of retained samples and review of batch records. The Party not directing an investigation shall have the right to conduct at its own expense any further tests it deems appropriate regarding such investigation provided that it shall share the results with the other Party. Any information provided by a Party shall be considered such Party‚Äôs Confidential Information and may be used or disclosed only as permitted under Article XIII hereof.\n",
      "(c) Reporting.\n",
      "(i) The Party directing an investigation shall provide to the other Party [***], and [***].\n",
      "(ii) Any final report regarding a Nonconformity shall be submitted by  within [***] of the notification regarding that Nonconformity given under Section 6.4 above.\n",
      "(iii)  shall provide to  a written report of [***]. Each Party shall hold all communications related to such investigation, testing or other requested assistance in confidence, and those communications shall be subject to the terms of Article XIII hereof.\n",
      "(d) Costs of Investigations.  shall reimburse  for [***] incurred by  in connection with [***].  shall reimburse  for [***] incurred by  in connection with [***].\n",
      "(e) Notwithstanding the foregoing, in the event it is determined in ‚Äôs reasonable discretion that API supplied by  hereunder was not the cause of a Product complaint or Adverse Event,  shall have no further obligation under this Section 6.8 except to reasonably cooperate with ‚Äôs investigation upon reasonable request by .\n",
      "21\n",
      "6.9 Certain Product Events.\n",
      "(a) Notification and Cooperation. In the event that  shall be required (or shall voluntarily decide) to initiate a recall, withdrawal or field correction of, field alert report or comparable report with respect to any Product,  shall notify ‚Äôs authorized quality assurance officer, and  shall reasonably cooperate with  to implement the same.\n",
      "(b) Coordination of Efforts. In the event that  becomes aware of information that may warrant  taking any action with respect to any Product,  shall immediately provide the  head of regulatory affairs such information. The Parties shall cooperate with each other in determining the necessity and nature of such action; provided, however, that  shall take no action to effect the same without the written concurrence of .\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 9 (Length: 9922 characters):\n",
      "(c) Reporting.\n",
      "(i) The Party directing an investigation shall provide to the other Party [***], and [***].\n",
      "(ii) Any final report regarding a Nonconformity shall be submitted by  within [***] of the notification regarding that Nonconformity given under Section 6.4 above.\n",
      "(iii)  shall provide to  a written report of [***]. Each Party shall hold all communications related to such investigation, testing or other requested assistance in confidence, and those communications shall be subject to the terms of Article XIII hereof.\n",
      "(d) Costs of Investigations.  shall reimburse  for [***] incurred by  in connection with [***].  shall reimburse  for [***] incurred by  in connection with [***].\n",
      "(e) Notwithstanding the foregoing, in the event it is determined in ‚Äôs reasonable discretion that API supplied by  hereunder was not the cause of a Product complaint or Adverse Event,  shall have no further obligation under this Section 6.8 except to reasonably cooperate with ‚Äôs investigation upon reasonable request by .\n",
      "21\n",
      "6.9 Certain Product Events.\n",
      "(a) Notification and Cooperation. In the event that  shall be required (or shall voluntarily decide) to initiate a recall, withdrawal or field correction of, field alert report or comparable report with respect to any Product,  shall notify ‚Äôs authorized quality assurance officer, and  shall reasonably cooperate with  to implement the same.\n",
      "(b) Coordination of Efforts. In the event that  becomes aware of information that may warrant  taking any action with respect to any Product,  shall immediately provide the  head of regulatory affairs such information. The Parties shall cooperate with each other in determining the necessity and nature of such action; provided, however, that  shall take no action to effect the same without the written concurrence of .\n",
      "(c) Contacts and Statements. With respect to any recall, withdrawal, field correction, field alert report or comparable report with respect to any Product,  or its designee shall make all contacts with the applicable Governmental Body and shall be responsible for coordinating all of the necessary activities in connection with any such recall, withdrawal, field correction, field alert report or comparable report.  or its designee shall make all statements to the media, including press releases and interviews for publication or broadcast.  agrees to make no statement to the media, unless otherwise required by Legal Requirements, and, in any such event,  shall reasonably collaborate with  on the content of any such statement.\n",
      "(d) Other Notice. Notwithstanding anything herein,  agrees to notify  as promptly as possible of any incident pertaining to the Product or API that would require notification to any Governmental Body, including, but not limited to, fire, explosion, environmental event, serious injury or physical damage at the Facility or -controlled facility related to the API Third Party Materials, or Intermediate.\n",
      "Article VII\n",
      "Regulatory Matters\n",
      "7.1 Consents.  shall obtain and hold all Consents required to be obtained by  under the Legal Requirements for the performance of its obligations under this Agreement and  shall reasonably cooperate with  with respect thereto. At all times,  shall maintain and comply with all of the Consents which may from time to time be required by any Governmental Body having jurisdiction with respect to ‚Äôs manufacturing operations and facilities and otherwise to be obtained by  to permit the performance of its then-current obligations under this Agreement.  shall bear all expenses incurred in connection with its obligations under this Section 7.1. In the event any Consent held by  relating to the Facility or its ability to manufacture the API in accordance with this Agreement is hereafter suspended or revoked, or  has material restrictions imposed upon it by any Governmental Body affecting the API or the Facility,  shall immediately provide written notification to  identifying such material restrictions, a schedule of compliance and such other information related thereto as is reasonably requested by . Without limiting the foregoing,  will cooperate with  in a reasonable and timely manner in preparation for pre-approval inspection of API manufactured at the Facility by any Governmental Body.\n",
      "22\n",
      "7.2 Establishment of cGMP Facility.\n",
      "(a)  shall use commercially reasonable best efforts to perform the work under the Development and Process Validation Plan relating to the Facility by the date or dates specified therein in order to establish the Facility as a cGMP facility by the date specified in the Development and Process Validation Plan and  shall reasonably cooperate with  with respect thereto.\n",
      "(b)  shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed. If  undertakes such an audit,  shall provide  with a written audit report and, if applicable, shall highlight therein areas where  judges that  needs to make changes to procedures or facilities in advance of any Pre-Approval Inspection. Both Parties shall cooperate in good faith to agree and implement the necessary changes. If ‚Äôs written audit report identifies any areas for improvement, within [***] following delivery of ‚Äôs audit report,  shall prepare an action plan (and promptly deliver a copy of such plan to  for review and comment), which plan shall address the findings of the audit report and include accomplishment dates for corrective actions. Thereafter, once the Parties mutually agree on a corrective action plan, the Parties agree to amend the Development and Process Validation Plan to include such corrective actions.\n",
      "(c)  agrees to cooperate with  by making its Approved Representatives available for consultation and advice to , as may be reasonably requested by , regarding implementation of cGMP and related procedural systems and any other matters as may be mutually agreed.\n",
      "(d)  shall use reasonable best efforts to be prepared for any Pre-Approval Inspection.  will cooperate with  in a reasonable and timely manner in preparation for such Pre-Approval Inspection.\n",
      "7.3 Compliance. In carrying out their respective obligations under this Agreement, the Parties shall comply in all respects with cGMPs and the Legal Requirements, as applicable to such Party, in effect from time to time.\n",
      "7.4 Drug Application Documentation.\n",
      "(a)  shall draft the CMC section of the Drug Application for the Product based on information to be provided by  as follows: (i) the Quality Section for API manufacturing (in the CMC section) will be drafted by  in the form of a DMF that will be sent to the FDA Documentation room by ; (ii)  will make available to  information in the DMF that does not constitute  Confidential Information; and (iii) such access to the DMF will be only through a letter of access issued to  by . Once the CMC section of the Drug Application for the Product is drafted by , if requested by ,  shall assist  by critically reviewing and providing corrections to any relevant section of the ‚Äôs CMC in a timely fashion.  agrees that  may reference  as the manufacturer of the API in ‚Äôs Drug Application and any other documentation required under any regulatory filings for the API, and  will provide the relevant Government Body with all required documentation, including development and analytical reports to support such filings.  shall own all regulatory files (excluding the DMFs) with respect to the API including without limitation regulatory data and documentation prepared by  under this Section 7.4 respecting the\n",
      "23\n",
      "manufacture of the API, including without limitation the CMC section of any Drug Application filed with the FDA related to the API. For the avoidance of doubt, (i) the DMFs shall be owned by , and (ii) all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide the relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner.\n",
      "(b) Upon reasonable request from ,  shall provide  with information regarding Drug Applications, or discrete sections thereof, to the extent available and necessary for  to perform its obligations under this Agreement; provided, however, that information provided hereunder shall not be provided or disclosed to any other Person without ‚Äôs prior Consent. In the event that any Governmental Body makes an inquiry of or provides any information to  that is or may be related to a Drug Application,  shall promptly forward such inquiry or information to .\n",
      "7.5 DMFs.  shall create and maintain the Drug Master Files for API in the [***] (if designated by  in its reasonable discretion) and other jurisdictions agreed to by the Parties (the ‚ÄúDMFs‚Äù).  agrees to assist  by making its Approved Representatives available for consultation and advice to , as may be reasonably requested by , regarding preparation and maintenance of the DMFs.  hereby grants to  the right to reference the DMFs in any relevant Drug Application or other documentation to the extent such reference is necessary for the approval and maintenance of a Drug Application. The Approved Representatives may share with  any information they receive or obtain in connection with their activities under this Section 7.5. Additionally, from time to time during the Term,  shall provide such information as  may reasonably request related to the DMFs, which shall be handled by  as  Confidential Information, subject to Article XIII.  shall own all regulatory files with respect to the API including without limitation the DMFs.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 10 (Length: 9477 characters):\n",
      "(b) Upon reasonable request from ,  shall provide  with information regarding Drug Applications, or discrete sections thereof, to the extent available and necessary for  to perform its obligations under this Agreement; provided, however, that information provided hereunder shall not be provided or disclosed to any other Person without ‚Äôs prior Consent. In the event that any Governmental Body makes an inquiry of or provides any information to  that is or may be related to a Drug Application,  shall promptly forward such inquiry or information to .\n",
      "7.5 DMFs.  shall create and maintain the Drug Master Files for API in the [***] (if designated by  in its reasonable discretion) and other jurisdictions agreed to by the Parties (the ‚ÄúDMFs‚Äù).  agrees to assist  by making its Approved Representatives available for consultation and advice to , as may be reasonably requested by , regarding preparation and maintenance of the DMFs.  hereby grants to  the right to reference the DMFs in any relevant Drug Application or other documentation to the extent such reference is necessary for the approval and maintenance of a Drug Application. The Approved Representatives may share with  any information they receive or obtain in connection with their activities under this Section 7.5. Additionally, from time to time during the Term,  shall provide such information as  may reasonably request related to the DMFs, which shall be handled by  as  Confidential Information, subject to Article XIII.  shall own all regulatory files with respect to the API including without limitation the DMFs.\n",
      "7.6 Regulatory Changes. The Parties will promptly notify each other of any material revisions, amendment of or additions to the DMFs and cGMPs and will confer with each other with respect to the best means to comply with such requirements.\n",
      "7.7 Regulatory Inspections.\n",
      "(a) Procedures. If  is notified that API or the portion of the Facility relating to the supply of API will be subject to an inspection by any Governmental Body,  shall:\n",
      "(i) within [***] advise ‚Äôs head of regulatory affairs, or his or her designee, by telephone and facsimile and provide all relevant information known to  regarding such inspection;\n",
      "(ii) reasonably cooperate with and allow any such inspection to the extent required by Legal Requirements;\n",
      "(iii) direct all inquiries related to API, Product, any Drug Application or ‚Äôs Confidential Information covered by Article XIII of this Agreement to ;\n",
      "(iv) have a consultant with the required expertise present for such inspections at ‚Äôs sole cost and expense.  will provide a copy of the 483 inspection observations upon conclusion of the inspection and the 483 responses to  when prepared and sent to the inspecting Governmental Body;\n",
      "24\n",
      "(v) within [***] (within [***] if any serious or critical deficiencies are identified by the Governmental Body) send  a copy of any inspection report observations issued by any Governmental Body related to the manufacture, generation, processing, storage, transportation, distribution, treatment, disposal or other management of API or Third Party Materials;\n",
      "(vi) provide each proposed response to any inspection reports prepared in accordance with this Section 7.7 not less than [***] before the required response date and consider any comments or suggestions received from  in good faith; and\n",
      "(vii) respond to all inspection report observations by any Governmental Body in a timely manner and take all appropriate corrective actions required or recommended by such Governmental Body.\n",
      "Notwithstanding the foregoing provisions of this Section 7.7(a), nothing shall require  to disclose information to  specifically relating to any other customer of  or those customers‚Äô products to which the inspection relates.\n",
      "(b) Notification. If any Governmental Body shall take any action which shall require a response or action by  with respect to API, Product, API Specifications, Third Party Materials, the Facility or any operating procedure affecting the API,  agrees [***] to notify  of the required response or action and, in the case of API, Product and/or API Specifications, shall proceed only with the prior advice and written Consent of , which shall not be unreasonably withheld or delayed. Notwithstanding anything contained in this Agreement to the contrary,  shall not initiate or participate in any communications with any Governmental Body concerning the API, Product or the API Specifications unless required to do so by Legal Requirements or requested to do so by  and only after consultation with .\n",
      "7.8 Other Regulatory Matters.  shall provide to each Governmental Body and, at ‚Äôs request, shall provide to , all documents and information requested by each such Governmental Body in support of ‚Äôs and ‚Äôs regulatory filings, including, without limitation, all relevant DMFs. Copies of all documents to be provided to any Governmental Body shall be provided to  at least [***] in advance of delivery to such Governmental Body, if possible, or otherwise as soon as practicable thereafter.\n",
      "7.9 Confidential Information. Notwithstanding anything to the contrary contained herein,  may redact or limit from any deliveries of or access to data, reports or any other information, any Third Party confidential information or  Confidential Information, at ‚Äôs sole discretion; provided, however, that  may not redact or limit any  Confidential Information that is reasonably necessary for  to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide the relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to  under this Article VII is  Confidential Information and nothing in this Article VII shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).\n",
      "25\n",
      "Article VIII\n",
      "Intellectual Property\n",
      "8.1 Ownership.\n",
      "(a)  Ownership.  acknowledges and agrees that  owns all rights in and to the  Intellectual Property, including all Intellectual Property rights in and to the API and the documentation, specifications and processes associated with the API. Except as expressly provided in Section 8.3 below, nothing in this Agreement shall be deemed to transfer or convey, expressly or by implication, any license or any other right, title or interest in or to the  Intellectual Property.\n",
      "(b)  Ownership.  acknowledges and agrees that  owns all rights in and to the  Intellectual Property, including all Intellectual Property rights in and to the Product, the Drug Applications, and the documentation, specifications and processes associated with the Product that is not  Intellectual Property.  does not have, by virtue of this Agreement or otherwise, a license or any other right, title or interest in or to the  Intellectual Property.\n",
      "8.2 New Developments.\n",
      "(a) API Product Developments. All Intellectual Property relating to the API or the development or manufacture of the API, that is conceived, reduced to practice, authored or otherwise invented, discovered, generated or developed in whole or in part by  in the course of activities under this Agreement, whether patentable or not, and any authorship of works relating to the API that are created by , including but not limited to any trademarks, trade dress, trade secrets or copyrights, shall be ‚ÄúAPI Product Developments.‚Äù\n",
      "(b) Ownership of API Product Developments. Subject to the rights and licenses granted in Section 8.3 below,  shall own all right, title and interest in and to all API Product Developments and all rights to Intellectual Property arising therefrom.\n",
      "(c) Patents. Notwithstanding any obligation of confidentiality between  and  under Section 13.3 hereto or any other agreement, , at its own expense, may elect to file and prosecute appropriate patent applications and maintain patents issuing therefrom covering such API Product Development. Upon ‚Äôs reasonable request and at its expense,  shall take such reasonable actions as  deems necessary or appropriate to assist  in obtaining patent or other proprietary protection in ‚Äôs name with respect to all API Product Developments. If  declines to pursue a patent for an API Product Development,  shall be obligated to assign its rights to pursue such patent to  and shall provide reasonable assistance if  decides to file a patent application for an API Product Development.\n",
      "8.3 Grant of License to API (including API Product Developments). Subject to the terms and conditions of this Agreement,  hereby grants  (a) a worldwide, non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment under Section 16.4), non-sublicensable license to use the API Product Developments for the manufacture and sale of Product using API supplied by , and (b) a worldwide, non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment under Section 16.4), non-sublicensable license to use\n",
      "26\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 11 (Length: 7325 characters):\n",
      "(b) Ownership of API Product Developments. Subject to the rights and licenses granted in Section 8.3 below,  shall own all right, title and interest in and to all API Product Developments and all rights to Intellectual Property arising therefrom.\n",
      "(c) Patents. Notwithstanding any obligation of confidentiality between  and  under Section 13.3 hereto or any other agreement, , at its own expense, may elect to file and prosecute appropriate patent applications and maintain patents issuing therefrom covering such API Product Development. Upon ‚Äôs reasonable request and at its expense,  shall take such reasonable actions as  deems necessary or appropriate to assist  in obtaining patent or other proprietary protection in ‚Äôs name with respect to all API Product Developments. If  declines to pursue a patent for an API Product Development,  shall be obligated to assign its rights to pursue such patent to  and shall provide reasonable assistance if  decides to file a patent application for an API Product Development.\n",
      "8.3 Grant of License to API (including API Product Developments). Subject to the terms and conditions of this Agreement,  hereby grants  (a) a worldwide, non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment under Section 16.4), non-sublicensable license to use the API Product Developments for the manufacture and sale of Product using API supplied by , and (b) a worldwide, non-exclusive, royalty-free, non-transferable (except in connection with a permitted assignment under Section 16.4), non-sublicensable license to use\n",
      "26\n",
      "the  Intellectual Property (other than the API Product Developments) for the manufacture and sale of Product using API supplied by . This license shall terminate upon the later of (i) the expiration or termination of this Agreement or (ii) such time that  is no longer in possession of API supplied by , including API that has been incorporated into Product that has not reached expiry. For the avoidance of doubt, regardless of the termination or expiration of this Agreement,  shall have a license to use the  Intellectual Property (including API Product Developments) for the manufacture and sale of the Product for so long as necessary to sell all inventory that incorporates API (including API Product Developments) provided by  under this Agreement. The license granted in this Section 8.3 shall be referred to as the ‚Äú License.‚Äù\n",
      "8.4 Infringement.\n",
      "(a)  shall promptly notify  of any suspected or threatened infringement, misappropriation or other unauthorized use of the  Intellectual Property licensed by  to  under the  License that comes to ‚Äôs attention. The notice shall set forth the facts of such suspected or threatened infringement in reasonable detail.  shall have the sole right, but not the obligation, to institute, prosecute and control, at its expense, any action or proceeding against the Third-Party infringer of such  Intellectual Property. If  institutes an action against such infringer,  shall give  reasonable assistance and authority to control, file and prosecute the suit as necessary at ‚Äôs expense.  shall have the right to participate in the applicable action or proceeding with its own counsel at its own expense and without reimbursement hereunder. If  elects to so participate,  shall provide  with an opportunity to consult regarding such action or proceeding.\n",
      "(b) If  elects not to bring any action or proceeding for infringement, misappropriation or other unauthorized use of the  Intellectual Property licensed by  to  under the  License, then it shall promptly advise  of its decision, and  thereafter shall have the right, but not the obligation, to institute, prosecute and control, at its expense, any action or proceeding against the Third-Party infringer of such  Intellectual Property. If  institutes an action against such infringer,  shall give  reasonable assistance and authority to control, file and prosecute the suit as necessary at ‚Äôs expense, and shall join such action if reasonably requested by  or required by applicable Legal Requirements.  shall have the right to participate in the applicable action or proceeding with its own counsel at its own expense and without reimbursement hereunder (except for any out-of-pocket costs and expenses incurred by  following its joinder as a party to such action or proceeding pursuant to ‚Äôs reasonable request or as required by applicable Legal Requirements). If  elects to participate (but is not joined as a party to such action or proceeding),  shall provide  with an opportunity to consult regarding such action or proceeding.  shall retain any damages or other monetary awards that it recovers in pursuing any action under this Section 8.4(b).\n",
      "(c) In the event that either Party exercises the rights conferred in this Section 8.4 and recovers any damages or other sums in such action or proceeding or in settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith (including attorneys fees), unless such Party is expressly not entitled to reimbursement under this Section 8.4. If such recovery is insufficient to cover all such costs and expenses of both Parties, the controlling Party‚Äôs costs shall be paid in full first before any of the other Party‚Äôs costs. Each Party seeking reimbursement under this Section 8.4 shall furnish promptly to the other Party appropriate documentation of its out-of-pocket costs and expenses incurred.\n",
      "27\n",
      "8.5 Data. As between  and ,  shall be and remain the sole and exclusive owner of any and all data and information, in any form, relating to: (a) the business of ; (b) licensees, customers and suppliers of ; (c) the Product and the development and manufacture thereof (excluding ‚Äôs data and information related to the API); and (d) the API Specifications. All information provided to  by  under this Article VIII shall be handled by  as  Confidential Information, subject to Article XIII.\n",
      "28\n",
      "Article IX\n",
      "Information; Access; Audit Rights\n",
      "9.1 Provision of Information.\n",
      "(a) Data.  shall provide to  copies (in electronic or hard-copy form, as requested by ) of or access to data as may be reasonably requested from time to time by  on a bona fide need-to-know basis, except as may be restricted for confidential information or trade secrets.  shall provide final reports for batch failures, including recommendation for API disposition for all investigations involving (i) foreign matter or particulate contamination; or (ii) any test results indicating non-compliance with the applicable Drug Applications, cGMPs or the API Specifications.\n",
      "(b) Annual Report.  shall prepare and provide to  a written annual report no later than [***] following the end of each Calendar Year, documenting, subject to redaction of  Confidential Information, (i) the prior Calendar Year‚Äôs batch records; (ii) packaging changes; (iii) process changes; (iv) changes in API testing methods performed pursuant to Article VI hereof; (v) changes in API Specifications; (vi) batches of API rejected or aborted; (vii) any other discrepancies that require reporting pursuant to cGMP or Legal Requirements; (viii) ‚Äútrends‚Äù in the manufacture of API during the prior Calendar Year; and (ix) ICH stability data summary.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 12 (Length: 9674 characters):\n",
      "27\n",
      "8.5 Data. As between  and ,  shall be and remain the sole and exclusive owner of any and all data and information, in any form, relating to: (a) the business of ; (b) licensees, customers and suppliers of ; (c) the Product and the development and manufacture thereof (excluding ‚Äôs data and information related to the API); and (d) the API Specifications. All information provided to  by  under this Article VIII shall be handled by  as  Confidential Information, subject to Article XIII.\n",
      "28\n",
      "Article IX\n",
      "Information; Access; Audit Rights\n",
      "9.1 Provision of Information.\n",
      "(a) Data.  shall provide to  copies (in electronic or hard-copy form, as requested by ) of or access to data as may be reasonably requested from time to time by  on a bona fide need-to-know basis, except as may be restricted for confidential information or trade secrets.  shall provide final reports for batch failures, including recommendation for API disposition for all investigations involving (i) foreign matter or particulate contamination; or (ii) any test results indicating non-compliance with the applicable Drug Applications, cGMPs or the API Specifications.\n",
      "(b) Annual Report.  shall prepare and provide to  a written annual report no later than [***] following the end of each Calendar Year, documenting, subject to redaction of  Confidential Information, (i) the prior Calendar Year‚Äôs batch records; (ii) packaging changes; (iii) process changes; (iv) changes in API testing methods performed pursuant to Article VI hereof; (v) changes in API Specifications; (vi) batches of API rejected or aborted; (vii) any other discrepancies that require reporting pursuant to cGMP or Legal Requirements; (viii) ‚Äútrends‚Äù in the manufacture of API during the prior Calendar Year; and (ix) ICH stability data summary.\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Such audits may be conducted [***] each [***]; provided, however, that  may conduct additional ‚Äúfor cause‚Äù audits during a [***] to the extent  supplies Nonconforming API or in the event of Product complaints or Adverse Events caused by Nonconforming API.  may redact from such deliveries to  any Third Party confidential information or  Confidential Information. During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).  agrees to reasonably cooperate and assist  (and to require any Material Third Party Supplier or Subcontractor to cooperate and assist ) in connection with any audits or inspections pursuant to this Section 9.2. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Approved Representatives at least [***] in advance; provided, however, that, in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of  or a Material Third Party Supplier or Subcontractor) or other similar event or emergency involving any API or Third Party Materials, Approved Representatives shall have the right at any time, upon written notice to  (or any Material Third Party Supplier or Subcontractor) of [***], to conduct an audit or inspection of those affected portions of the Facility (or the facility of such Material Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of API and Third Party Materials.  shall ensure that Approved Representatives have access to Material Third Party Supplier‚Äôs and Subcontractor‚Äôs facilities in the manner set forth in this Section 9.2.  shall as soon as practicable take any corrective action reasonably requested by  in connection with this Section 9.2.\n",
      "29\n",
      "9.3 Record Retention. Each Party shall maintain, in accordance with and for the period required under the applicable Drug Application, cGMPs and Legal Requirements, complete and adequate records pertaining to all activities in connection with, and facilities used for, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API, Third Party Materials and Product.\n",
      "9.4 Confidential Information. Notwithstanding anything to the contrary contained in this Agreement,  may redact or limit from any deliveries of or access to data, reports or any other information any Third Party confidential information or  Confidential Information, at ‚Äôs sole discretion; provided, however, that  may not redact or limit any  Confidential Information that is reasonably necessary for  to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide the relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, all information provided to  under this Article IX is, subject to Section 13.4,  Confidential Information and nothing in this Article IX shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).\n",
      "Article X\n",
      "Representations and Warranties\n",
      "10.1 Representations and Warranties of .  represents and warrants that:\n",
      "(a) Compliance. The manufacture, generation, processing, distribution, transport, treatment, storage, disposal and other handling of any Third Party Materials and API by  shall be in accordance with and conform to the API Specifications, cGMPs, ICH guidelines, all Legal Requirements, this Agreement and the Quality Agreement. The API shall comply with the applicable Drug Applications, cGMPs, API Specifications, ICH guidelines and Legal Requirements; shall be free from defects in materials and workmanship; and shall not be adulterated or misbranded within the meaning of applicable Legal Requirements.\n",
      "(b) Status; Enforceability.  is a validly existing corporation in good standing under the laws of the jurisdiction of its incorporation; the execution, delivery and performance of this Agreement by  has been duly authorized by all requisite corporate action; this Agreement constitutes a legal, valid and binding obligation of , enforceable against  in accordance with the terms hereof; and the execution, delivery and performance of this Agreement by  will not violate or conflict with any other agreement or instrument to which  is a party.\n",
      "(c) Certain Persons.  has not used, and will not use, in any capacity associated with or related to the manufacture of the API, the services of any Persons who have been, or are in the process of being, (i) debarred under 21 U.S.C. ¬ß 335a(a) or (b) or any comparable Legal Requirements, or (ii) excluded from participation in the Medicare program, any state Medicaid program or any other health care program. Furthermore, neither  nor any of its officers, employees or consultants has been convicted of an offense under\n",
      "30\n",
      "(x) either a federal or state law that is cited in 21 U.S.C. ¬ß 335(a) as a ground for debarment, denial of approval or suspension, (y) any other law cited in any comparable Legal Requirements as a ground for debarment, denial of approval or suspension.  shall notify  immediately upon learning of any circumstance that would cause this certification under this Section 10.1(c) to become false or inaccurate.\n",
      "(d) Regulatory Consents.  has or will have all Consents necessary to timely perform its obligations hereunder and to manufacture the API used in Product for commercial sale.\n",
      "(e) Maintenance of Facility. During the Term of this Agreement,  shall maintain the Facility, required local licenses, the equipment used to manufacture the API,  Intellectual Property and any applicable contracts necessary to manufacture the API in accordance with the API Specifications, Legal Requirements, cGMPs, the Quality Agreement and ‚Äôs standard operating procedures.\n",
      "(f) Negative Pledge. The transfer of the API by  to  is and shall be rightful and free and clear of any liens or encumbrances.\n",
      "(g) Security Measures.  shall maintain reasonable security policies at the Facility and shall use commercially reasonable efforts to have security measures in place to protect the integrity of the API, Third Party Materials, data and works-in-process at the Facility.\n",
      "(h) Non-Infringement. To ‚Äôs best knowledge, ‚Äôs performance of its obligations under this Agreement will not infringe upon, nor cause ‚Äôs use of the API to infringe upon, the Intellectual Property rights of any Third Party.\n",
      "10.2 Representations and Warranties of .  represents and warrants that:\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 13 (Length: 9793 characters):\n",
      "30\n",
      "(x) either a federal or state law that is cited in 21 U.S.C. ¬ß 335(a) as a ground for debarment, denial of approval or suspension, (y) any other law cited in any comparable Legal Requirements as a ground for debarment, denial of approval or suspension.  shall notify  immediately upon learning of any circumstance that would cause this certification under this Section 10.1(c) to become false or inaccurate.\n",
      "(d) Regulatory Consents.  has or will have all Consents necessary to timely perform its obligations hereunder and to manufacture the API used in Product for commercial sale.\n",
      "(e) Maintenance of Facility. During the Term of this Agreement,  shall maintain the Facility, required local licenses, the equipment used to manufacture the API,  Intellectual Property and any applicable contracts necessary to manufacture the API in accordance with the API Specifications, Legal Requirements, cGMPs, the Quality Agreement and ‚Äôs standard operating procedures.\n",
      "(f) Negative Pledge. The transfer of the API by  to  is and shall be rightful and free and clear of any liens or encumbrances.\n",
      "(g) Security Measures.  shall maintain reasonable security policies at the Facility and shall use commercially reasonable efforts to have security measures in place to protect the integrity of the API, Third Party Materials, data and works-in-process at the Facility.\n",
      "(h) Non-Infringement. To ‚Äôs best knowledge, ‚Äôs performance of its obligations under this Agreement will not infringe upon, nor cause ‚Äôs use of the API to infringe upon, the Intellectual Property rights of any Third Party.\n",
      "10.2 Representations and Warranties of .  represents and warrants that:\n",
      "(a) Status; Enforceability.  is a validly existing corporation in good standing under the laws of the jurisdiction of its incorporation; the execution, delivery and performance of this Agreement by  has been duly authorized by all requisite corporate action; this Agreement constitutes the legal, valid and binding obligation of , enforceable against  in accordance with the terms hereof; and the execution, delivery and performance of this Agreement by  will not violate or conflict with any other agreement or instrument to which  is a party.\n",
      "(b) Certain Persons.  has not used, and will not use, in any capacity associated with or related to the Product, the services of any Persons who have been, or are in the process of being, (i) debarred under 21 U.S.C. ¬ß 335a(a) or (b) or any comparable Legal Requirements, or (ii) excluded from participation in the Medicare program, any state Medicaid program or any other health care program. Furthermore, neither  nor any of its officers, employees or consultants has been convicted of an offense under (x) either a federal or state law that is cited in 21 U.S.C. ¬ß 335(a) as a ground for debarment, denial of approval or suspension, (y) any other law cited in any comparable Legal Requirements as a ground for debarment, denial of approval or suspension.  shall notify  immediately upon learning of any circumstance that would cause this certification under this Section 10.2(b) to become false or inaccurate.\n",
      "(c) Regulatory Consents.  has all Consents necessary to perform its obligations hereunder and will, prior to commercial sale of Product, have all Consents necessary for the commercial sale of Product once Product is approved by FDA or any other Governmental Body.\n",
      "31\n",
      "(d) Non-infringement. To ‚Äôs best knowledge, ‚Äôs commercial sale of Product will not infringe upon the Intellectual Property rights of any Third Party.\n",
      "10.3 Disclaimer. OTHER THAN AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTIES, EITHER EXPRESS OR IMPLIED, AND THE PARTIES EXPRESSLY DISCLAIM ALL IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NONINFRINGEMENT.\n",
      "Article XI\n",
      "Liability and Indemnification\n",
      "11.1 Indemnity by .  shall defend, indemnify and hold harmless  and ‚Äôs Affiliates and licensees and distributors and its and their respective directors, officers, employees and agents from and against all Losses to the extent arising out of or resulting from (a) any breach, nonperformance or failure to comply with any of ‚Äôs covenants, agreements, obligations, representations or warranties under this Agreement or the terms of this Agreement; or (b) negligence, recklessness, gross negligence or wrongful intentional acts or omissions by, or strict liability of,  or  Affiliates, their respective directors, officers, employees, agents or Subcontractors.\n",
      "11.2 Indemnity by .  shall defend, indemnify and hold harmless  and ‚Äôs Affiliates and its and their respective directors, officers, employees and agents from and against all Losses to the extent arising out of or resulting from (a) any breach, nonperformance or failure to comply with any of ‚Äôs covenants, agreements, obligations, representations or warranties under this Agreement or the terms of this Agreement; or (b) negligence, recklessness, gross negligence or wrongful intentional acts or omissions by, or strict liability of,  or  Affiliates, their respective directors, officers, employees, agents or contractors.\n",
      "11.3 Procedures. Any person that may be entitled to indemnification under this Agreement (an ‚ÄúIndemnified Party‚Äù) shall give written notice to the Person obligated to indemnify it (an ‚ÄúIndemnifying Party‚Äù) with reasonable promptness upon becoming aware of any claim or other facts upon which a claim for indemnification will be based. The notice shall set forth such information with respect thereto as is then reasonably available to the Indemnified Party. The Indemnifying Party shall have the right to undertake the defense of any such claim with counsel reasonably satisfactory to the Indemnified Party, and the Indemnified Party shall cooperate in such defense and make available all records, materials and witnesses reasonably requested by the Indemnifying Party at the Indemnifying Party‚Äôs expense. If the Indemnifying Party shall have assumed the defense of the claim with counsel reasonably satisfactory to the Indemnified Party, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by the Indemnified Party in connection with the defense thereof. The Indemnifying Party shall not be liable for any claim settled without its Consent, which Consent shall not be unreasonably withheld. The Indemnifying Party shall obtain the written Consent of the Indemnified Party, which shall not be unreasonably withheld, prior to ceasing to defend, settling or otherwise disposing of any claim if, as a result thereof, the Indemnified Party would become subject to injunctive or other equitable relief or if the Indemnified Party may reasonably object to such disposition of such claim based on a continuing adverse effect on the Indemnified Party.\n",
      "11.4 Special Indemnity. In the event this Agreement is terminated by  pursuant to Section 15.5(a),  shall pay to  the amount of [***], which shall be ‚Äôs sole and exclusive remedy with respect thereto, and in the event this Agreement is terminated by  pursuant to Section 15.5(g),  shall pay to  the amount of [***], which shall be ‚Äôs sole and exclusive remedy with respect thereto.\n",
      "32\n",
      "11.5 Limitation of Liability. Subject to Section 11.6, in no event, regardless of the form of the claim or cause of action, whether based on contract, warranty, infringement, tort, strict liability or otherwise, shall a Party‚Äôs cumulative liability for claims under or relating to this Agreement, including, but not limited to, liquidated damages for delay in delivery or Nonconformity, exceed the aggregate amount of [***].\n",
      "11.6 No Special Damages. Notwithstanding anything to the contrary contained herein, except for breaches of confidentiality obligations, the Parties shall not be liable to each other for any special, indirect, incidental or consequential damages (including for lost profits).\n",
      "Article XII\n",
      "Insurance\n",
      "12.1 Coverage Requirements. Each Party shall maintain in full force and effect beginning no later than [***] and during the remaining Term of this Agreement and for a period of [***] after expiration or termination of this Agreement, worker‚Äôs compensation, property, general liability and product liability insurance coverage in such amounts and with such scope of coverages as are adequate to cover such Party‚Äôs obligations under this Agreement and as are customary in the industry for companies of like size and activities and taking into account the nature of the API to be manufactured under this Agreement and the Product. Without limiting any of the foregoing, (a) each Party‚Äôs product liability insurance coverage limits shall be no less than [***]; (b) ‚Äôs insurance shall include coverage for [***]; and (c) ‚Äôs policy(ies) shall include [***]. Each Party shall provide evidence of such insurance to the other Party and ensure that the other Party will receive no less than [***] notice of any cancellation, non-renewal or material change in the policy(ies).\n",
      "Article XIII\n",
      "Confidentiality\n",
      "13.1 Definition of ‚Äú Confidential Information‚Äù. As used herein, the term ‚Äú Confidential Information‚Äù shall mean all confidential business and technical communications, documents and other information, in each case not constituting  Confidential Information,  Intellectual Property or data, whether in written, oral or other form, which  or an  Affiliate furnishes or discloses to  or which  otherwise learns in connection with the negotiation or performance of this Agreement (whether relating to , an  Affiliate or any Third Party for which  has an obligation of confidentiality), including the API Specifications and the terms of this Agreement and any information disclosed by  prior to the Effective Date.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 14 (Length: 9876 characters):\n",
      "Article XII\n",
      "Insurance\n",
      "12.1 Coverage Requirements. Each Party shall maintain in full force and effect beginning no later than [***] and during the remaining Term of this Agreement and for a period of [***] after expiration or termination of this Agreement, worker‚Äôs compensation, property, general liability and product liability insurance coverage in such amounts and with such scope of coverages as are adequate to cover such Party‚Äôs obligations under this Agreement and as are customary in the industry for companies of like size and activities and taking into account the nature of the API to be manufactured under this Agreement and the Product. Without limiting any of the foregoing, (a) each Party‚Äôs product liability insurance coverage limits shall be no less than [***]; (b) ‚Äôs insurance shall include coverage for [***]; and (c) ‚Äôs policy(ies) shall include [***]. Each Party shall provide evidence of such insurance to the other Party and ensure that the other Party will receive no less than [***] notice of any cancellation, non-renewal or material change in the policy(ies).\n",
      "Article XIII\n",
      "Confidentiality\n",
      "13.1 Definition of ‚Äú Confidential Information‚Äù. As used herein, the term ‚Äú Confidential Information‚Äù shall mean all confidential business and technical communications, documents and other information, in each case not constituting  Confidential Information,  Intellectual Property or data, whether in written, oral or other form, which  or an  Affiliate furnishes or discloses to  or which  otherwise learns in connection with the negotiation or performance of this Agreement (whether relating to , an  Affiliate or any Third Party for which  has an obligation of confidentiality), including the API Specifications and the terms of this Agreement and any information disclosed by  prior to the Effective Date.\n",
      "13.2 Definition of ‚Äú Confidential Information‚Äù. As used herein, the term ‚Äú Confidential Information‚Äù shall mean (a) all confidential business information, and (b) technical communications, documents or other information, in each case not constituting  Confidential Information,  Intellectual Property or data, whether in written, oral or other form, of  or a  Affiliate that are disclosed to  by  or a  Affiliate or  otherwise learns in connection with the negotiation or performance of this Agreement (whether relating to , a  Affiliate or any Third Party for which  has an obligation of confidentiality), including the terms of this Agreement and any information disclosed by  prior to the Effective Date. The fact that a Party is required by a provision of this Agreement to disclose certain information to the other Party shall not have any effect regarding whether such information is  Confidential Information or  Confidential Information, as the case may be, and all use\n",
      "33\n",
      "and disclosure of such Confidential Information is subject to this Article XIII. In responding to such a required disclosure, a Party may redact information relating to Third Parties from any documents deliverable to the other Party that are not relevant to the subject matter of this Agreement.\n",
      "13.3 Treatment of Confidential Information. Both during the Term of this Agreement and thereafter,  Confidential Information and  Confidential Information (collectively for this Section 13.3 ‚ÄúConfidential Information‚Äù) shall be treated in accordance with the requirements of this Article XIII.\n",
      "(a) Nondisclosure and Non-Use. A Party receiving Confidential Information of the other Party shall (i) maintain in confidence such Confidential Information to the same extent such Party maintains its own proprietary information of similar kind and value (but at a minimum each Party shall use commercially reasonable efforts to maintain Confidential Information in confidence); (ii) not disclose such Confidential Information to any Third Party without prior written Consent of the disclosing Party, except, in the case of , for disclosures to ‚Äôs licensees and commercial partners for the Product who agree to be bound by obligations of non-disclosure and non-use at least as stringent as those contained in this Article XIII; and (iii) not use such Confidential Information for any purpose except those purposes permitted by this Agreement.\n",
      "(b) Exceptions. Notwithstanding any other provision of this Agreement, the receiving Party may disclose Confidential Information of the disclosing Party to a Third Party: (i) to the extent and to the Persons as required by an applicable Legal Requirements, legal process or court order, or an applicable disclosure requirement of any Governmental Body, the U.S. Securities and Exchange Commission, the Nasdaq market or any other securities exchange or market; or (ii) to the extent necessary to exercise the rights granted to the receiving Party under this Agreement in filing or prosecuting patent applications, prosecuting or defending litigation or otherwise establishing rights or enforcing obligations under this Agreement, or conducting clinical trials or seeking regulatory approval of the Product; provided, however, that the receiving Party shall first have given prompt notice to the disclosing Party to enable the disclosing Party to seek any available exemptions from or limitations on any applicable disclosure requirement and shall reasonably cooperate in such efforts by the disclosing Party.  shall reasonably cooperate with  in providing prospective commercial partners with access to the Facility during normal business hours and allowing the prospective partners to perform reasonable due diligence related to the manufacture and supply of API hereunder to the extent such access to the Facility or information does not interfere with the daily operation of ‚Äôs business, and subject to ‚Äôs right to deny access to or disclosure of  Confidential Information at ‚Äôs sole and absolute discretion. Notwithstanding, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  or any prospective commercial partners under any circumstances.\n",
      "(c) Terms of Agreement. The Parties agree that the existence of and the material terms of this Agreement shall be considered Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth below in this Section 13.3(c) (in lieu of the authorized disclosure provisions set forth in Section 13.3(b), to the extent of any conflict) and without limiting the generality of the definition of Confidential Information set forth in Sections 13.1 and 13.2. If either Party desires to make a public announcement concerning this Agreement or the terms hereof, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval. A Party shall not be required to seek the permission of the other Party to repeat any information as to the existence\n",
      "34\n",
      "and terms of this Agreement that has already been publicly disclosed by such Party in accordance with the foregoing or by the other Party. Either Party may disclose the terms of this Agreement to such Party‚Äôs existing investors, directors and professional advisors and to potential investors, acquirors or merger partners and their professional advisors who are bound by written or professional obligations of non disclosure and non-use that are at least as stringent as those contained in this Article XIII or are customary for such purpose.  acknowledges that  or its Affiliates may be obligated to file a copy of this Agreement with the U.S. Securities and Exchange Commission with its next quarterly report on Form 10-Q, annual report on Form 10-K or current report on Form 8-K or with any registration statement filed with the U.S. Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended, and  shall be entitled to make such filings.\n",
      "13.4 Excluded Information. Notwithstanding any provision herein to the contrary, the requirements of this Article XIII shall not apply to any information of either Party which:\n",
      "(a) at the time of disclosure hereunder is generally available to the public;\n",
      "(b) after disclosure hereunder becomes generally available to the public, except through breach of this Article XIII by the receiving Party or its Affiliates;\n",
      "(c) was not acquired directly or indirectly from the disclosing Party or its Affiliates and which the receiving Party lawfully had in its possession prior to disclosure by the disclosing Party without confidentiality, nondisclosure and non-use obligations;\n",
      "(d) is independently developed by employees or agents of the receiving Party without the use of the Confidential Information of the disclosing Party; or\n",
      "(e) becomes available to the receiving Party from a Third Party that is not legally prohibited from disclosing such Confidential Information, provided such information was not acquired by such Third Party directly or indirectly from the disclosing Party or its Affiliates.\n",
      "13.5 Return of Confidential Information. At any time upon the request of the other Party, to the extent such Confidential Information is not reasonably necessary to enable a Party to perform its obligations under this Agreement, or upon expiration or termination of this Agreement, the Party receiving Confidential Information will cease its use and, upon request, within thirty (30) days either return or destroy (and certify as to such destruction) all Confidential Information of the other Party, including any copies or other embodiments thereof, except that the receiving Party may retain a copy for archive purposes. The return and/or destruction of such Confidential Information as provided above shall not relieve the receiving Party of its other obligations under this Article XIII.\n",
      "\n",
      "\n",
      "-----------------\n",
      "\n",
      "üîπüîπüîπ Chunk 15 (Length: 9981 characters):\n",
      "13.4 Excluded Information. Notwithstanding any provision herein to the contrary, the requirements of this Article XIII shall not apply to any information of either Party which:\n",
      "(a) at the time of disclosure hereunder is generally available to the public;\n",
      "(b) after disclosure hereunder becomes generally available to the public, except through breach of this Article XIII by the receiving Party or its Affiliates;\n",
      "(c) was not acquired directly or indirectly from the disclosing Party or its Affiliates and which the receiving Party lawfully had in its possession prior to disclosure by the disclosing Party without confidentiality, nondisclosure and non-use obligations;\n",
      "(d) is independently developed by employees or agents of the receiving Party without the use of the Confidential Information of the disclosing Party; or\n",
      "(e) becomes available to the receiving Party from a Third Party that is not legally prohibited from disclosing such Confidential Information, provided such information was not acquired by such Third Party directly or indirectly from the disclosing Party or its Affiliates.\n",
      "13.5 Return of Confidential Information. At any time upon the request of the other Party, to the extent such Confidential Information is not reasonably necessary to enable a Party to perform its obligations under this Agreement, or upon expiration or termination of this Agreement, the Party receiving Confidential Information will cease its use and, upon request, within thirty (30) days either return or destroy (and certify as to such destruction) all Confidential Information of the other Party, including any copies or other embodiments thereof, except that the receiving Party may retain a copy for archive purposes. The return and/or destruction of such Confidential Information as provided above shall not relieve the receiving Party of its other obligations under this Article XIII.\n",
      "13.6 Redaction of  Confidential Information. Notwithstanding ‚Äôs right to redact or limit  Confidential Information from deliveries of or access to data, reports or any other information,  may not redact or limit any  Confidential Information that is reasonably necessary for  to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide any relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to  under this Agreement is  Confidential Information and nothing in this Agreement shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be expressly permitted under this Agreement).\n",
      "35\n",
      "Article XIV\n",
      "Force Majeure Event\n",
      "14.1 General. Except for any obligation to pay money, neither Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation of this Agreement when such failure or delay is due to a Force Majeure Event, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, a ‚ÄúForce Majeure Event‚Äù is defined as: acts of God; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; failure of public utilities and similar events which are beyond the reasonable control of the Party affected. In the event of a Force Majeure Event,  or , as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any Force Majeure Event.\n",
      "14.2 Termination Due to Event of Force Majeure; Transition. If, as a result of the conditions referred to in Section 14.1, a Party is unable to fully perform its obligations for a period of [***], the other Party shall have the right to terminate this Agreement upon [***] prior notice to the non-performing Party.\n",
      "Article XV\n",
      "Term; Termination; Remedies\n",
      "15.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated by either Party in accordance with this Article XV, will continue until the seventh (7 ) anniversary of the approval of the\n",
      "th\n",
      "Drug Application by the FDA (the ‚ÄúInitial Term‚Äù) and shall renew automatically for successive five (5) year renewal terms unless either Party notifies the other Party of its intent to not renew by providing written notice to the other Party no less than two (2) years prior to the expiration of the Initial Term or applicable renewal term. The Initial Term together with any renewal term(s) is the ‚ÄúTerm.‚Äù\n",
      "15.2 Termination for Breach. This Agreement may be terminated by either Party in the event of the material breach by the other Party of the terms and conditions hereof; provided, however, the other Party shall first give to the breaching Party written notice of the proposed termination or cancellation of this Agreement, specifying the grounds therefor. Upon receipt of such notice, the breaching Party shall have sixty (60) days to respond by curing such breach. If the breaching Party does not cure such breach within such cure period, then (a) if  is the breaching Party,  (i) shall have the right to terminate this Agreement and (ii) shall have the remedies set forth in Section 15.6; or (b) if  is the breaching Party,  shall (i) have the right to terminate this Agreement and (ii) shall have the remedies set forth in Section 15.8.\n",
      "15.3 Insolvency; Bankruptcy. To the extent permitted by Legal Requirements, each Party will have the right to terminate this Agreement immediately upon notice to the other Party, if any of the following occurs: (a) such other Party is declared bankrupt or insolvent, (b) such other Party generally fails to pay its debts as they become due, (c) there is an assignment for the benefit of such other Party‚Äôs creditors, (d) a receiver is appointed or there is a voluntary or involuntary petition filed or an action or proceeding commenced for bankruptcy, reorganization, dissolution or winding up of such other Party that is not dismissed within sixty (60) days, or (e) there is a foreclosure or sale of a material part of such other Party‚Äôs assets by or for the benefit of any creditor or governmental agency.\n",
      "36\n",
      "15.4 Discontinuance or Suspension of Product Program.  may terminate this Agreement upon thirty (30) days‚Äô written notice to  if , in its sole and absolute discretion, discontinues or indefinitely suspends the development and/or commercialization of the Product. Upon the termination of this Agreement pursuant to this Section 15.4, ‚Äôs sole obligation shall be for it to reimburse  for all documented direct costs and expenses properly and reasonably incurred by  pursuant to this Agreement up to the effective date of such termination in connection with ‚Äôs then-outstanding obligation to purchase quantities of API forecasted with respect to the binding portion of an applicable [***] Forecast; provided, however, that  shall use commercially reasonable efforts to mitigate such costs and expenses by cancelling any cancelable orders for Third Party Materials, returning returnable Third Party Materials, and/or using non-returnable Third Party Materials for its own or its other customers‚Äô behalf. For avoidance of doubt, if  terminates this Agreement pursuant to this Section 15.4,  shall be obligated to purchase the quantities set forth in any Purchase Orders and quantities set forth in any binding portion of a [***] Forecast, but not obligated to purchase any minimum purchase requirements set forth in Section 2.2.\n",
      "15.5 Termination by . Without limiting any other Section of this Article XV,  may terminate this Agreement upon thirty (30) days‚Äô written notice to  upon the occurrence of any of the following:\n",
      "(a) Failure to Validate Manufacturing Process.  fails to complete the Validation of the Initial Manufacturing Process on or before the Expansion completion date set forth in Section 4.1.\n",
      "(b) Failure to Achieve Acceptance of Pre-Approval Inspection.  (i) receives at any time correspondence from FDA indicating that the Facility or facility of a Third Party Supplier is not approved for the manufacture of API, or (ii) fails to obtain official correspondence from FDA stating that the Facility has been approved for the manufacture of API on or before the [***] after the first FDA inspection of the Facility relating to the Expansion.\n",
      "(c) Failure to Supply Unrelated to Force Majeure. In the event of the continued failure of  to deliver API to ,  shall have the right to terminate this Agreement upon thirty (30) days‚Äô prior written notice to . ‚ÄúContinued‚Äù for purposes of determining a continued failure to supply shall be a failure to deliver at least [***] of the API required to be delivered over a [***] period.\n",
      "(d) Supply of Nonconforming API.  delivers Nonconforming API pursuant to [***] or more Purchase Orders in any [***] period.\n",
      "(e) Late Shipment.  ships API pursuant to [***] or more Purchase Orders after the applicable Shipment Date during any [***] period.\n",
      "(f) Failure to Obtain or Maintain Consents.  fails to obtain, maintain and comply with all Consents required for the performance of its obligations under this Agreement.\n",
      "\n",
      "\n",
      "-----------------\n"
     ]
    }
   ],
   "source": [
    "# Print first few chunks \n",
    "for i, chunk in enumerate(document_chunks[:15]):\n",
    "    print(f\"\\nüîπüîπüîπ Chunk {i+1} (Length: {len(chunk)} characters):\\n{chunk}\\n\\n\")\n",
    "    print(\"-----------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "59ac83d4-6cf7-4106-899c-4e7e5a302acc",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "cb169e6e-9403-4328-bd39-cf9d51f876e6",
   "metadata": {},
   "source": [
    "## Import Requirements"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "21c5808c-b028-442a-babe-d000882ed64d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "from langgraph.prebuilt import create_react_agent\n",
    "from langgraph_supervisor import create_supervisor\n",
    "\n",
    "\n",
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5696d77e-341f-4b93-9de4-89c7c7e21ace",
   "metadata": {},
   "source": [
    "## Import ENVs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "d9f3871f-5bc5-4668-b613-0936c6f5915e",
   "metadata": {},
   "outputs": [],
   "source": [
    "dotenv_path = 'D:\\\\Dhananjay\\\\Pro\\\\DCode\\\\MyAIPractice\\\\.env'\n",
    "\n",
    "# import dotenv\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "# Load environment variables\n",
    "load_dotenv(dotenv_path)\n",
    "\n",
    "GEMINI_API_KEY = os.getenv(\"GEMINI_API_KEY\")\n",
    "GEMINI_LLM_MODEL_NAME = os.getenv(\"GEMINI_LLM_MODEL_NAME\")\n",
    "GEMINI_EMBEDDING_MODEL_NAME = os.getenv(\"GEMINI_EMBEDDING_MODEL_NAME\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "83a1073d-ef8e-4599-9bea-f8cd386ab06d",
   "metadata": {},
   "source": [
    "## Initialize LLM (Google Gemini)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "d241441c-e901-4383-99be-fd4e0fe8ac68",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Initialize LLM (Google Gemini)\n",
    "model = ChatGoogleGenerativeAI(\n",
    "    google_api_key=GEMINI_API_KEY,\n",
    "    model=GEMINI_LLM_MODEL_NAME,\n",
    "    temprature = 0\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "89d0ea50-226a-4297-9afe-51600c9e11cd",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_google_genai import GoogleGenerativeAIEmbeddings\n",
    "\n",
    "def get_embedding_model():\n",
    "    \"\"\"\n",
    "    Returns the configured embedding model for vector storage and retrieval.\n",
    "    \"\"\"\n",
    "    google_embedding = GoogleGenerativeAIEmbeddings(\n",
    "        model=GEMINI_EMBEDDING_MODEL_NAME,\n",
    "        google_api_key=GEMINI_API_KEY\n",
    "    )\n",
    "\n",
    "    return google_embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "9f9abd68-c6f7-43c2-aff2-b666aebd9da7",
   "metadata": {},
   "outputs": [],
   "source": [
    " from langchain_core.documents import Document\n",
    "\n",
    "# Convert text chunks to LangChain Document objects\n",
    "documents = [Document(page_content=chunk) for chunk in document_chunks]\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "53dce804-78ab-4847-b4ea-61e64f2ed76b",
   "metadata": {},
   "source": [
    "## Retriever"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "87a8c0b9-070b-474c-bb45-ef79f2aa7794",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "67effd97-ee9d-4f50-a85f-d13d5e98cb39",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.vectorstores import Chroma\n",
    "\n",
    "\n",
    "# Add to vectorDB\n",
    "vectorstore = Chroma.from_documents(\n",
    "    documents=documents,\n",
    "    collection_name=\"extract-clause-chroma\",\n",
    "    embedding=get_embedding_model(),\n",
    "    persist_directory=\"./chroma_langchain_db\",  #  save data locally\n",
    "\n",
    ")\n",
    "\n",
    "retriever = vectorstore.as_retriever()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e9a884e3-8e59-4f73-a844-246842680c79",
   "metadata": {},
   "source": [
    "###  Create Retriever Tool"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "60c838ec-48b7-4a2c-8644-4f278e50e65a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "34829\n"
     ]
    }
   ],
   "source": [
    "from langchain.tools.retriever import create_retriever_tool\n",
    "\n",
    "# Create a retriever tool to extract \"Audit & Inspection Rights\" clauses\n",
    "retriever_tool = create_retriever_tool(\n",
    "    retriever,  \n",
    "    \"retrieve_audit_inspection_clauses\",\n",
    "    \"Extract all occurrences of the 'Audit & Inspection Rights' clause from the document. \"\n",
    ")\n",
    "\n",
    "# Define tools list\n",
    "tools = [retriever_tool]\n",
    "\n",
    "# Example usage (if integrated in an agent-based workflow)\n",
    "result = retriever_tool.invoke(\"Find all 'Audit & Inspection Rights' clauses in the document\")\n",
    "print(len(result))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "34c4ff73-ec2c-4c2c-8ab7-889ead51e6bb",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "ad2f117a-cc9a-49e6-9c83-305486394410",
   "metadata": {},
   "source": [
    "# Agents"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e9b344c0-b363-4e11-89a9-ca673d14f88b",
   "metadata": {},
   "source": [
    "### Audit_Inspection_Extraction_Agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "a059e382-b3d3-42aa-8a83-f42276d6027c",
   "metadata": {},
   "outputs": [],
   "source": [
    "Audit_Inspection_Extraction_Agent_Prompt = \"\"\"Extract all possible occurrences of the \"Audit & Inspection Rights\" clause from the provided document.\n",
    "\n",
    "Identify clauses that explicitly grant one party the right to:\n",
    "- Audit or inspect the books, records, accounts, or financial documents of another party.\n",
    "- Inspect or examine the premises, facilities, or operational sites of the other party.\n",
    "\n",
    "The extracted clauses should contain a contractual obligation related to audits or inspections.\n",
    "\n",
    "Return **only** the exact clause text as it appears in the contract. Do **not** generate any additional text, summaries, or explanations.\n",
    "\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "aba89add-26df-4f7a-a727-c25eff77751e",
   "metadata": {},
   "outputs": [],
   "source": [
    "Audit_Inspection_Extraction_Agent = create_react_agent(\n",
    "    model=model,\n",
    "    tools=[],\n",
    "    name=\"Audit Inspection Extraction Agent\",\n",
    "    prompt=Audit_Inspection_Extraction_Agent_Prompt\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a6242970-20ce-48ee-b2f0-b52d423f2fa8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "90ca8205-a485-4b26-ad2f-89441a709e50",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "8237630b-253d-4e90-ae7e-cccad6a3f3c9",
   "metadata": {},
   "source": [
    "### KeyClauseConceptsAgent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "2413315a-0062-4ab4-a0d6-fce24cf761f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "Key_Clause_Concepts_Agent_Prompt = \"\"\"Ensure the extracted clause strictly follows the scope of \"Audit & Inspection Rights.\" \n",
    "\n",
    "Only validate clauses that explicitly grant one party the right to audit, inspect, or examine the books, records, accounts, or premises of the other party. \n",
    "\n",
    "Exclude any clauses related to government/regulatory audits, product inspections, or definitions of \"auditor.\"\n",
    "\n",
    "Return only the exact text from the contract document. Do not include any explanations, summaries, or extra text.\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "44289d42-c972-4ddf-8698-e301ef88689f",
   "metadata": {},
   "outputs": [],
   "source": [
    "Key_clause_concepts_agent = create_react_agent(\n",
    "    model=model,\n",
    "    tools=[],\n",
    "    name=\"Key ClauseConcepts Agent\",\n",
    "    prompt=Key_Clause_Concepts_Agent_Prompt\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "919704ab-470b-4e78-86f7-19267c7dd772",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "a5a105e9-71a6-4fc9-90ae-408ff2683a7a",
   "metadata": {},
   "source": [
    "### FeatureCheckAgent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "a9c8a3d2-1f9f-49ca-97ce-42cadf4cf864",
   "metadata": {},
   "outputs": [],
   "source": [
    "Expected_Key_Clause_Feature_Agent_Prompt = \"\"\"Ensure the clause contains at least one of the following rights:  \n",
    "\n",
    "- The right of one party to audit the books and records of another party.  \n",
    "- The right of one party to give or receive access to the books and records of another party.  \n",
    "- The right to inspect or examine the premises, books, accounts, records, papers, or other specified items.  \n",
    "- The obligation of one party to maintain or retain records, files, books, accounts, or papers for the purpose of audit or inspection.  \n",
    "- The obligation of a party to follow certain procedures and rules with respect to conducting the audit.  \n",
    "\n",
    "Reject clauses that do not meet this requirement.  \n",
    "\n",
    "Return only the exact clause text from the contract document. Do not generate any additional content.\n",
    "\n",
    "\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "c2d3dd47-13d2-4d10-9ba2-1e3250e0f27b",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "Feature_Check_Agent = create_react_agent(\n",
    "    model=model,\n",
    "    tools=[],\n",
    "    name=\"Feature Check Agent\",\n",
    "    prompt=Expected_Key_Clause_Feature_Agent_Prompt\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "39e4179f-3d51-446e-8e26-d5f271fbf7d6",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "6dd13995-682e-4665-91dd-ee317aa67e9d",
   "metadata": {},
   "source": [
    "### ExclusionFilterAgent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "a42e7254-e5ba-4ce8-a576-db8b10d075fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "Exclude_Clause_Concepts_Agent_Prompt = \"\"\"\n",
    "Filter out any clauses that fall into the following exclusions:  \n",
    "\n",
    "- Governmental or regulatory audits and inspections.  \n",
    "- Inspection rights on the delivery of products, especially those related to acceptance testing.  \n",
    "- Definitions of the term \"auditor.\"  \n",
    "\n",
    "Reject any clause that fits these exclusions.  \n",
    "\n",
    "Return only the exact clause text from the contract document. Do not add any explanations or extra text.\n",
    "\n",
    "\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "04b9445d-fc96-44f6-9c49-c8172a85dda7",
   "metadata": {},
   "outputs": [],
   "source": [
    "Exclusion_Filter_Agent = create_react_agent(\n",
    "    model=model,\n",
    "    tools=[],\n",
    "    name=\"Exclusion Filter Agent\",\n",
    "    prompt=Exclude_Clause_Concepts_Agent_Prompt\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "86754b36-0d48-4b67-82e8-94943bbc573d",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "9bdb46cf-70f9-4b3b-b7cb-aa86f40b4b0c",
   "metadata": {},
   "source": [
    "### supervised workflow"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "60a8c132-4cd8-4090-9797-4dc19c7d6d08",
   "metadata": {},
   "outputs": [],
   "source": [
    "Supervisor_Workflow_Prompt = \"\"\"You are a team supervisor managing Audit Inspection Extraction Agent, Feature Check Agent, and Exclusion Filter Agent. \n",
    "        To extract all occurrences of \"Audit & Inspection Rights\" clauses, use Audit_Inspection_Extraction_Agent. \n",
    "        To verify if the extracted clauses align with the expected key clause features, use Feature_Check_Agent.\n",
    "        To remove any extracted clauses that match the excluded concepts, use Exclusion_Filter_Agent\n",
    "\n",
    "        Extract all occurrences of `Audit & Inspection Rights` clauses, verify if the extracted clauses align with the expected key clause features, and remove any extracted clauses that match the excluded concepts.\n",
    "\n",
    "        Return only the exact clause text provided. Do not generate any summaries, explanations, or extra text.\n",
    "\n",
    "        If no valid clause is found, return `\"NO CLAUSE FOUND\"`.  \n",
    "        \n",
    "\n",
    "        \"\"\"\n",
    "\n",
    "        # If no valid clause is found, return `\"NO CLAUSE FOUND\"`.  \n",
    "# "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "9fb26c2b-66d6-4e65-80a9-5ea0bb762625",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "workflow = create_supervisor(\n",
    "    [Audit_Inspection_Extraction_Agent, Feature_Check_Agent, Exclusion_Filter_Agent],  \n",
    "    model=model,\n",
    "    prompt=Supervisor_Workflow_Prompt\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "d314b8e9-9d1c-4129-8ed6-4a71e3cc6d5d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Compile \n",
    "app = workflow.compile()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "36753112-03c6-4a73-9890-882b09c44ba5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "17"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(document_chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "3ce9cd49-11a8-40f1-8860-25d1ec67fa22",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I am sorry, but based on the text you provided, there are no \"Audit & Inspection Rights\" clauses.\n",
      "-------------------\n",
      "5.7 Audit Rights.  shall have the right, but not the obligation, to audit the Facility, including the systems and standard operating procedures used to manufacture API for , to assess ‚Äôs compliance with cGMP and the requirements of this Agreement.  shall have the right, but not the obligation, to audit ‚Äôs Third Party Suppliers and Subcontractors to assess their compliance with cGMP and the requirements of this Agreement.  may exercise such audit rights upon reasonable advance notice to  and at reasonable times and intervals.  shall bear the cost of any such audits, unless a material breach of cGMP or this Agreement is discovered during any such audit, in which case  shall bear the reasonable cost of such audit.  shall have the right to be present during any audit of a Third Party Supplier or Subcontractor.\n",
      "-------------------\n",
      "I am sorry, but there are no \"Audit & Inspection Rights\" clauses in the text provided.\n",
      "-------------------\n",
      "Within [***] from the date of receipt of written notice of any API Price change,  may request  to provide its API Price adjustment records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by  are correct and in accordance with the methodology described in Schedule 3.1(e).\n",
      "-------------------\n",
      "I am unable to locate any clauses related to \"Audit & Inspection Rights\" in the provided text.\n",
      "-------------------\n",
      "(i) The Parties shall participate in project teleconferences with each other as reasonably requested by the other Party to successfully complete the Validation of the Initial Manufacturing Process. During development and Validation of the Initial Manufacturing Process,  will accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by . Without limiting the foregoing, during process development and in support of API process characterization and Validation activities,  will be permitted to conduct reviews of the Facility and the pertinent records maintained by , subject to restriction on access to all  Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon ‚Äôs request and with reasonable notice to permit  to support such technical reviews.\n",
      "\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "-------------------\n",
      "shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "-------------------\n",
      "I am unable to find the \"Audit & Inspection Rights\" clause in the provided document.\n",
      "-------------------\n",
      "7.2 Establishment of cGMP Facility.\n",
      "(b)  shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed.\n",
      "-------------------\n",
      "I am sorry, but I could not find any \"Audit & Inspection Rights\" clauses in the provided text.\n",
      "-------------------\n",
      "Article IX\n",
      "Information; Access; Audit Rights\n",
      "-------------------\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials.\n",
      "During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).\n",
      "-------------------\n",
      "There are no clauses related to \"Audit & Inspection Rights\" in the provided text.\n",
      "-------------------\n",
      "I am unable to find any clauses related to \"Audit & Inspection Rights\" in the provided text.\n",
      "-------------------\n",
      "I am sorry, but there are no \"Audit & Inspection Rights\" clauses within the provided text.\n",
      "-------------------\n",
      "No clause in the provided text explicitly grants audit or inspection rights.\n",
      "-------------------\n",
      "There are no clauses related to \"Audit & Inspection Rights\" in the provided text.\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "sup_document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "sup_result_list = []\n",
    "\n",
    "\n",
    "for sup_doc in sup_document_text_list:\n",
    "\n",
    "    su_messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": sup_doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    sup_result = Audit_Inspection_Extraction_Agent.invoke(su_messages)\n",
    "    \n",
    "    sup_result_content = sup_result[\"messages\"][-1].content\n",
    "    sup_result_list.append(sup_result_content)\n",
    "    print(sup_result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "6e90946e-d34e-447e-a401-c7b6e7412f4c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "7.2 Establishment of cGMP Facility.\n",
      "(b)  shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed.\n",
      "-------------------\n",
      "I am sorry, but I could not find any clauses related to \"Audit & Inspection Rights\" in the provided document.\n",
      "-------------------\n",
      "Article IX\n",
      "Information; Access; Audit Rights\n",
      "-------------------\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials.\n",
      "\n",
      "During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).\n",
      "-------------------\n",
      "I am unable to find any clauses related to \"Audit & Inspection Rights\" in the provided text.\n",
      "-------------------\n",
      "I am unable to locate any clauses related to \"Audit & Inspection Rights\" within the provided document.\n",
      "-------------------\n",
      "I am sorry, but there is no \"Audit & Inspection Rights\" clause in the provided text.\n",
      "-------------------\n",
      "No clause in the provided text explicitly grants audit or inspection rights.\n",
      "-------------------\n",
      "I am sorry, but there are no clauses related to \"Audit & Inspection Rights\" in the provided text.\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "# sup_document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "sup_result_list_1 = []\n",
    "\n",
    "\n",
    "for sup_doc in sup_document_text_list[8:]:\n",
    "\n",
    "    su_messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": sup_doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    sup_result_1 = Audit_Inspection_Extraction_Agent.invoke(su_messages)\n",
    "    \n",
    "    sup_result_content_1 = sup_result_1[\"messages\"][-1].content\n",
    "    sup_result_list_1.append(sup_result_content_1)\n",
    "    print(sup_result_content_1)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "74d0e318-4c2e-49ca-ba62-b44d0f16901f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "9392bd6d-2646-4030-812a-81671214249c",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# Function to save extracted clauses to an Excel file\n",
    "def save_to_excel(extracted_text, output_path=\"Extracted_Audit_Clauses.xlsx\"):\n",
    "    df = pd.DataFrame({\"Extracted Content\": [extracted_text]})\n",
    "    df.to_excel(output_path, index=False)\n",
    "    print(f\" Extracted clauses saved to: {output_path}\")\n",
    "\n",
    "    \n",
    "# Function to extract and validate clauses\n",
    "def process_contract(docx_path):\n",
    "    document_text = load_and_chunk_document(docx_path)[12]\n",
    "    \n",
    "    \n",
    "    messages = {\n",
    "        \"messages\": [\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"content\": document_text\n",
    "            }\n",
    "        ]\n",
    "    }\n",
    "    \n",
    "    \n",
    "    validated_clauses = app.invoke(messages)\n",
    "\n",
    "    return validated_clauses\n",
    "    \n",
    "    # Step 3: Save to Excel\n",
    "    # save_to_excel(validated_clauses)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "result = process_contract(docx_path)\n",
    "\n",
    "\n",
    "# for m in result[\"messages\"]:\n",
    "#     m.pretty_print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "2a3d737f-6cbd-40c7-aa98-11b3ad3113ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "(d) Duties. In performing its duties under this Section 5.4,  shall perform the following tasks, consistent with the Quality Agreement:\n",
      "(i) implement and operate an ICH complaint stability program;\n",
      "(ii) notify ‚Äôs head of regulatory affairs, or his or her designee, promptly, but within not more than [***], if any batch of API fails any stability tests; and\n",
      "(iii) report to ‚Äôs head of regulatory affairs, or his or her designee, promptly, but within not more than [***], any Nonconformity, significant atypical results, deviations or adverse trends exhibited during final release or stability testing.\n",
      "(e) Manufacturing Process Review. At either Party‚Äôs reasonable request, the Parties shall promptly meet, in person or telephonically, for the purpose of reviewing such matters related to manufacturing of the API as may be specified by a Party, including discussing strategies for improving the API manufacturing processes.\n",
      "(f) Confidential Information. Notwithstanding anything to the contrary contained in this Agreement,  may redact or limit from any deliveries of or access to data, reports or any other information to  any Third Party confidential information or  Confidential Information, at ‚Äôs sole discretion; provided, however, that  may not redact or limit any  Confidential Information that is reasonably necessary for  to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide the relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to  under this Section 5.4 is  Confidential Information and nothing in this Section 5.4 shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).\n",
      "5.5 Third Party Materials.\n",
      "(a) General.  shall be responsible for procuring, inspecting, testing and releasing adequate Third Party Materials that comply with cGMP and this Agreement as necessary to meet a Purchase Order for API.  shall perform all testing of Third Party Materials required by the applicable API Specifications, cGMP, Legal Requirements, this Agreement and the Quality Agreement.\n",
      "16\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "(c) Materials Certifications.  shall prepare or cause to be prepared by its Third Party Suppliers all certifications as to any Third Party Materials required by cGMPs or Legal Requirements.\n",
      "5.6 Quality Agreement. Within [***] following the Effective Date, the Parties shall enter into a quality agreement with such scope, terms and conditions as are customary within the pharmaceutical industry (such agreement, the ‚ÄúQuality Agreement‚Äù). In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement, the provisions of this Agreement shall govern.\n",
      "5.7 Compliance with Specifications, cGMPs and Legal Requirements.  shall be responsible for identifying and implementing, in accordance with its obligations under Section 5.1, any actions required to bring , Material Third Party Suppliers and Third Party Suppliers of starting materials for the Compound into compliance with API Specifications, cGMPs and Legal Requirements.  shall implement any such changes as soon as reasonably practicable (even if, in the case of cGMPs and Legal Requirements, a later effective date is specified), unless the required effective date for implementing such change falls after the effective date of any termination of this Agreement for which notice has been previously given.\n",
      "Article VI\n",
      "Testing and Quality Assurance\n",
      "6.1 Quality Assurance; Quality Control; Retains.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: supervisor\n",
      "Tool Calls:\n",
      "  transfer_to_audit_inspection_extraction_agent (e737db50-24ca-46d7-aed1-73d3aee1b92a)\n",
      " Call ID: e737db50-24ca-46d7-aed1-73d3aee1b92a\n",
      "  Args:\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: transfer_to_audit_inspection_extraction_agent\n",
      "\n",
      "Successfully transferred to Audit Inspection Extraction Agent\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: Audit Inspection Extraction Agent\n",
      "\n",
      "```tool_code\n",
      "print(audit_inspection_extraction.extract_clauses(document=\"\"\"(d) Duties. In performing its duties under this Section 5.4,  shall perform the following tasks, consistent with the Quality Agreement:\n",
      "(i) implement and operate an ICH complaint stability program;\n",
      "(ii) notify ‚Äôs head of regulatory affairs, or his or her designee, promptly, but within not more than [***], if any batch of API fails any stability tests; and\n",
      "(iii) report to ‚Äôs head of regulatory affairs, or his or her designee, promptly, but within not more than [***], any Nonconformity, significant atypical results, deviations or adverse trends exhibited during final release or stability testing.\n",
      "(e) Manufacturing Process Review. At either Party‚Äôs reasonable request, the Parties shall promptly meet, in person or telephonically, for the purpose of reviewing such matters related to manufacturing of the API as may be specified by a Party, including discussing strategies for improving the API manufacturing processes.\n",
      "(f) Confidential Information. Notwithstanding anything to the contrary contained in this Agreement,  may redact or limit from any deliveries of or access to data, reports or any other information to  any Third Party confidential information or  Confidential Information, at ‚Äôs sole discretion; provided, however, that  may not redact or limit any  Confidential Information that is reasonably necessary for  to comply with all Legal Requirements. In this regard, the Parties agree that all process information related to the manufacture of API, whether contained in a DMF or otherwise, shall, subject to Section 13.4, constitute  Confidential Information and shall not be disclosed to  under any circumstances, notwithstanding anything herein to the contrary; provided, however,  shall provide the relevant Governmental Body with all information necessary to support ‚Äôs Drug Application filings in a timely manner. Furthermore, for the avoidance of doubt, subject to Section 13.4, all information provided to  under this Section 5.4 is  Confidential Information and nothing in this Section 5.4 shall be construed as giving  any right to use or disclose (A) any  Intellectual Property (except as may be permitted by any express license from ), or (B) any  Confidential Information (except as may be permitted under Article XIII hereof).\n",
      "5.5 Third Party Materials.\n",
      "(a) General.  shall be responsible for procuring, inspecting, testing and releasing adequate Third Party Materials that comply with cGMP and this Agreement as necessary to meet a Purchase Order for API.  shall perform all testing of Third Party Materials required by the applicable API Specifications, cGMP, Legal Requirements, this Agreement and the Quality Agreement.\n",
      "16\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "(c) Materials Certifications.  shall prepare or cause to be prepared by its Third Party Suppliers all certifications as to any Third Party Materials required by cGMPs or Legal Requirements.\n",
      "5.6 Quality Agreement. Within [***] following the Effective Date, the Parties shall enter into a quality agreement with such scope, terms and conditions as are customary within the pharmaceutical industry (such agreement, the ‚ÄúQuality Agreement‚Äù). In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement, the provisions of this Agreement shall govern.\n",
      "5.7 Compliance with Specifications, cGMPs and Legal Requirements.  shall be responsible for identifying and implementing, in accordance with its obligations under Section 5.1, any actions required to bring , Material Third Party Suppliers and Third Party Suppliers of starting materials for the Compound into compliance with API Specifications, cGMPs and Legal Requirements.  shall implement any such changes as soon as reasonably practicable (even if, in the case of cGMPs and Legal Requirements, a later effective date is specified), unless the required effective date for implementing such change falls after the effective date of any termination of this Agreement for which notice has been previously given.\n",
      "Article VI\n",
      "Testing and Quality Assurance\n",
      "6.1 Quality Assurance; Quality Control; Retains.\"\"\"))\n",
      "```\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: Audit Inspection Extraction Agent\n",
      "\n",
      "Transferring back to supervisor\n",
      "Tool Calls:\n",
      "  transfer_back_to_supervisor (02012900-b021-4cb0-9e7a-db03b445b789)\n",
      " Call ID: 02012900-b021-4cb0-9e7a-db03b445b789\n",
      "  Args:\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: transfer_back_to_supervisor\n",
      "\n",
      "Successfully transferred back to supervisor\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: supervisor\n",
      "Tool Calls:\n",
      "  transfer_to_feature_check_agent (1525650d-fd19-4568-bef6-a074f84c1246)\n",
      " Call ID: 1525650d-fd19-4568-bef6-a074f84c1246\n",
      "  Args:\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: transfer_to_feature_check_agent\n",
      "\n",
      "Successfully transferred to Feature Check Agent\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: Feature Check Agent\n",
      "\n",
      "```tool_code\n",
      "print(feature_check.extract_clauses(document=\"(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\"))\n",
      "```\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: Feature Check Agent\n",
      "\n",
      "Transferring back to supervisor\n",
      "Tool Calls:\n",
      "  transfer_back_to_supervisor (befb3ed7-60d9-4214-9947-6cfb32706215)\n",
      " Call ID: befb3ed7-60d9-4214-9947-6cfb32706215\n",
      "  Args:\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: transfer_back_to_supervisor\n",
      "\n",
      "Successfully transferred back to supervisor\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: supervisor\n",
      "Tool Calls:\n",
      "  transfer_to_exclusion_filter_agent (8a1b2a16-edf3-4d03-971e-849aa28a2e3d)\n",
      " Call ID: 8a1b2a16-edf3-4d03-971e-849aa28a2e3d\n",
      "  Args:\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: transfer_to_exclusion_filter_agent\n",
      "\n",
      "Successfully transferred to Exclusion Filter Agent\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: Exclusion Filter Agent\n",
      "\n",
      "```tool_code\n",
      "print(exclusion_filter.filter_clauses(clauses=[\"(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\"], exclusions=[\"Governmental or regulatory audits and inspections.\", \"Inspection rights on the delivery of products, especially those related to acceptance testing.\", \"Definitions of the term \\\"auditor.\\\"\"]))\n",
      "```\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: Exclusion Filter Agent\n",
      "\n",
      "Transferring back to supervisor\n",
      "Tool Calls:\n",
      "  transfer_back_to_supervisor (335d3b30-4b6d-4080-9e37-dea520d3f0df)\n",
      " Call ID: 335d3b30-4b6d-4080-9e37-dea520d3f0df\n",
      "  Args:\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "Name: transfer_back_to_supervisor\n",
      "\n",
      "Successfully transferred back to supervisor\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Name: supervisor\n",
      "\n",
      "(b) Audits. shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a). shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n"
     ]
    }
   ],
   "source": [
    "for m in result[\"messages\"]:\n",
    "    m.pretty_print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a91020a6-30c4-483b-8004-dc998c4adcad",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d41076bf-ba2b-4792-b1b3-12c0a9ba0a48",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "54251d8e-cac6-4be5-a209-09ae7f4b44eb",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b1be551e-a886-4dd4-84b1-bd87e9759157",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "0e3057c3-0b47-431e-aac0-1148b1dc5f06",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(document_chunks)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "51048e79-49d0-45ae-9f5e-bd17c9f72e4f",
   "metadata": {},
   "source": [
    "# Manual Chaining fo Agents"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3d138fad-6954-4342-a295-1bf5b449ffb7",
   "metadata": {},
   "source": [
    "## Start with the Audit_Inspection_Extraction_Agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "96a1263c-27de-44ea-a0ba-94d680442598",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "Within [***] from the date of receipt of written notice of any API Price change,  may request  to provide its API Price adjustment records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by  are correct and in accordance with the methodology described in Schedule 3.1(e).\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "result_list_1 = []\n",
    "\n",
    "\n",
    "for doc in document_text_list[:10]:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Audit_Inspection_Extraction_Agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    result_list_1.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1d9b150f-8018-4635-9476-55e4693904a3",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "411083c8-e1b3-49d2-aca0-b9db53994617",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "(i) During development and Validation of the Initial Manufacturing Process,  will accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by . Without limiting the foregoing, during process development and in support of API process characterization and Validation activities,  will be permitted to conduct reviews of the Facility and the pertinent records maintained by , subject to restriction on access to all  Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon ‚Äôs request and with reasonable notice to permit  to support such technical reviews.\n",
      "(iii) With the prior written consent of the other Party, a Party may engage in teleconferences, in person meetings, Facility reviews, quality assurance audits, records reviews and other activities under this Agreement through its (or its Affiliates‚Äô) employees or consultants with a bona fide need to know, but only to the extent necessary for the Party to exercise its rights and discharge its obligations under this Agreement, provided that (A) each such employee and consultant has executed a written confidentiality agreement containing use and disclosure restrictions at least as protective as those set forth in Article XIII, and (B) any  consultant shall be reasonably acceptable to  (such persons, ‚ÄúApproved Representatives‚Äù).\n",
      "-------------------\n",
      "```text\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "```\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "(b)  shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed.\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "# document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "result_list_2 = []\n",
    "\n",
    "\n",
    "for doc in document_text_list[10:20]:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Audit_Inspection_Extraction_Agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    result_list_2.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "7338baa2-262a-4fe0-bcf8-22ecd3b098d4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Such audits may be conducted [***] each [***]; provided, however, that  may conduct additional ‚Äúfor cause‚Äù audits during a [***] to the extent  supplies Nonconforming API or in the event of Product complaints or Adverse Events caused by Nonconforming API.  may redact from such deliveries to  any Third Party confidential information or  Confidential Information. During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).  agrees to reasonably cooperate and assist  (and to require any Material Third Party Supplier or Subcontractor to cooperate and assist ) in connection with any audits or inspections pursuant to this Section 9.2. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Approved Representatives at least [***] in advance; provided, however, that, in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of  or a Material Third Party Supplier or Subcontractor) or other similar event or emergency involving any API or Third Party Materials, Approved Representatives shall have the right at any time, upon written notice to  (or any Material Third Party Supplier or Subcontractor) of [***], to conduct an audit or inspection of those affected portions of the Facility (or the facility of such Material Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of API and Third Party Materials.  shall ensure that Approved Representatives have access to Material Third Party Supplier‚Äôs and Subcontractor‚Äôs facilities in the manner set forth in this Section 9.2.  shall as soon as practicable take any corrective action reasonably requested by  in connection with this Section 9.2.\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "# document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "result_list_3 = []\n",
    "\n",
    "\n",
    "for doc in document_text_list[20:25]:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Audit_Inspection_Extraction_Agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    result_list_3.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "e6081cad-925c-4ead-8d37-f7688ab49f30",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "# document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "result_list_4 = []\n",
    "\n",
    "\n",
    "for doc in document_text_list[25:30]:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Audit_Inspection_Extraction_Agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    result_list_4.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "09106bc5-b155-4b23-97b8-e658f968fd9f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n",
      "NO CLAUSE FOUND\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "# document_text_list = load_and_chunk_document(docx_path)\n",
    "\n",
    "result_list_5 = []\n",
    "\n",
    "\n",
    "for doc in document_text_list[30:]:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Audit_Inspection_Extraction_Agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    result_list_5.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5174d98e-f987-4551-afb5-3f8b6099be9e",
   "metadata": {},
   "source": [
    "# Get all possible occurrences of ‚ÄúAudit & Inspection Rights‚Äù clause"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "2e657ff4-03ac-41f4-bede-cf57431b80b9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Within [***] from the date of receipt of written notice of any API Price change,  may request  to provide its API Price adjustment records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by  are correct and in accordance with the methodology described in Schedule 3.1(e).\n",
      "----------\n",
      "(i) During development and Validation of the Initial Manufacturing Process,  will accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by . Without limiting the foregoing, during process development and in support of API process characterization and Validation activities,  will be permitted to conduct reviews of the Facility and the pertinent records maintained by , subject to restriction on access to all  Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon ‚Äôs request and with reasonable notice to permit  to support such technical reviews.\n",
      "(iii) With the prior written consent of the other Party, a Party may engage in teleconferences, in person meetings, Facility reviews, quality assurance audits, records reviews and other activities under this Agreement through its (or its Affiliates‚Äô) employees or consultants with a bona fide need to know, but only to the extent necessary for the Party to exercise its rights and discharge its obligations under this Agreement, provided that (A) each such employee and consultant has executed a written confidentiality agreement containing use and disclosure restrictions at least as protective as those set forth in Article XIII, and (B) any  consultant shall be reasonably acceptable to  (such persons, ‚ÄúApproved Representatives‚Äù).\n",
      "----------\n",
      "```text\n",
      "(b) Audits.  shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a).  shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "```\n",
      "----------\n",
      "(b)  shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed.\n",
      "----------\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Such audits may be conducted [***] each [***]; provided, however, that  may conduct additional ‚Äúfor cause‚Äù audits during a [***] to the extent  supplies Nonconforming API or in the event of Product complaints or Adverse Events caused by Nonconforming API.  may redact from such deliveries to  any Third Party confidential information or  Confidential Information. During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).  agrees to reasonably cooperate and assist  (and to require any Material Third Party Supplier or Subcontractor to cooperate and assist ) in connection with any audits or inspections pursuant to this Section 9.2. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Approved Representatives at least [***] in advance; provided, however, that, in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of  or a Material Third Party Supplier or Subcontractor) or other similar event or emergency involving any API or Third Party Materials, Approved Representatives shall have the right at any time, upon written notice to  (or any Material Third Party Supplier or Subcontractor) of [***], to conduct an audit or inspection of those affected portions of the Facility (or the facility of such Material Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of API and Third Party Materials.  shall ensure that Approved Representatives have access to Material Third Party Supplier‚Äôs and Subcontractor‚Äôs facilities in the manner set forth in this Section 9.2.  shall as soon as practicable take any corrective action reasonably requested by  in connection with this Section 9.2.\n",
      "----------\n"
     ]
    }
   ],
   "source": [
    "def merge_valid_clauses(*lists):\n",
    "    \"\"\"Merges multiple lists while removing 'NO CLAUSE FOUND' entries.\"\"\"\n",
    "    final_list = []\n",
    "    \n",
    "    for result_list in lists:\n",
    "        for clause in result_list:\n",
    "            if clause.strip().lower() != \"no clause found\":  # Ignore invalid clauses\n",
    "                final_list.append(clause)\n",
    "\n",
    "    return final_list\n",
    "\n",
    "\n",
    "\n",
    "# Merge lists while filtering out \"NO CLAUSE FOUND\"\n",
    "final_result_list = merge_valid_clauses(result_list_1, result_list_2, result_list_3, result_list_4, result_list_5)\n",
    "\n",
    "#  final merged list\n",
    "for cl in final_result_list:\n",
    "    print(cl)\n",
    "    print(\"----------\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "06ab9448-e00e-4587-aa32-f998c544d13f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "8e5210c4-f24f-4f8d-8535-8e60de02ced7",
   "metadata": {},
   "source": [
    "# Chain to Expected_key_clause_feature_agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "e8a061aa-9be1-4acb-9697-2e5cd2ca4fde",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Within [***] from the date of receipt of written notice of any API Price change, may request to provide its API Price adjustment records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by are correct and in accordance with the methodology described in Schedule 3.1(e).\n",
      "-------------------\n",
      "(i) During development and Validation of the Initial Manufacturing Process, will accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by . Without limiting the foregoing, during process development and in support of API process characterization and Validation activities, will be permitted to conduct reviews of the Facility and the pertinent records maintained by , subject to restriction on access to all Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon ‚Äôs request and with reasonable notice to permit to support such technical reviews.\n",
      "-------------------\n",
      "(b) Audits. shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a). shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "-------------------\n",
      "(b) shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed.\n",
      "-------------------\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Such audits may be conducted [***] each [***]; provided, however, that  may conduct additional ‚Äúfor cause‚Äù audits during a [***] to the extent  supplies Nonconforming API or in the event of Product complaints or Adverse Events caused by Nonconforming API.  may redact from such deliveries to  any Third Party confidential information or  Confidential Information. During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).  agrees to reasonably cooperate and assist  (and to require any Material Third Party Supplier or Subcontractor to cooperate and assist ) in connection with any audits or inspections pursuant to this Section 9.2. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Approved Representatives at least [***] in advance; provided, however, that, in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of  or a Material Third Party Supplier or Subcontractor) or other similar event or emergency involving any API or Third Party Materials, Approved Representatives shall have the right at any time, upon written notice to  (or any Material Third Party Supplier or Subcontractor) of [***], to conduct an audit or inspection of those affected portions of the Facility (or the facility of such Material Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of API and Third Party Materials.  shall ensure that Approved Representatives have access to Material Third Party Supplier‚Äôs and Subcontractor‚Äôs facilities in the manner set forth in this Section 9.2.  shall as soon as practicable take any corrective action reasonably requested by  in connection with this Section 9.2.\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "\n",
    "exp_result_list = []\n",
    "\n",
    "\n",
    "for doc in final_result_list:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Expected_key_clause_feature_agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    exp_result_list.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "828c2617-e3c3-47ef-a3e8-c3074e850716",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "a78e0482-e34f-46cd-b0e2-6dc3b7c7fa4f",
   "metadata": {},
   "source": [
    "# Chain to Exclude_clause_concepts_agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "4cc89348-abaf-484d-8742-a95921732fb2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Within [***] from the date of receipt of written notice of any API Price change, may request to provide its API Price adjustment records to an independent, mutually agreed upon, reputable certified public accounting firm, which will audit such records and certify whether the price adjustments notified by are correct and in accordance with the methodology described in Schedule 3.1(e).\n",
      "-------------------\n",
      "(i) During development and Validation of the Initial Manufacturing Process, will accommodate in person technical meetings at the Facility and technical inspections as reasonably requested by . Without limiting the foregoing, during process development and in support of API process characterization and Validation activities, will be permitted to conduct reviews of the Facility and the pertinent records maintained by , subject to restriction on access to all Confidential Information, in connection with the conduct of manufacturing, storage and testing of API, all upon ‚Äôs request and with reasonable notice to permit to support such technical reviews.\n",
      "-------------------\n",
      "(b) Audits. shall be responsible for selecting all Third Party Suppliers of materials for API and periodically performing audits of each such Material Third Party Supplier as necessary to ensure compliance with Section 5.5(a). shall provide the results of any such audit, including copies of any reports prepared in connection with any such audit, within [***] of the audit‚Äôs completion.\n",
      "-------------------\n",
      "(b) shall have the right, pursuant to the audit procedures in Section 9.2, to have its Approved Representatives undertake a quality assurance audit of ‚Äôs procedures and facilities for API production as soon as practicable after the date the Expansion is completed.\n",
      "-------------------\n",
      "9.2 Audit and Inspection Rights. During the Term of this Agreement and thereafter during any applicable records retention period(s) under Section 9.3, Approved Representatives shall have the right, upon a prior written consent of , not to be unreasonably withheld or delayed, to audit and inspect those portions of the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be) used in, and those documents and records related to, the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of the API and Third Party Materials. Such audits may be conducted [***] each [***]; provided, however, that  may conduct additional ‚Äúfor cause‚Äù audits during a [***] to the extent  supplies Nonconforming API or in the event of Product complaints or Adverse Events caused by Nonconforming API.  may redact from such deliveries to  any Third Party confidential information or  Confidential Information. During such inspections, Approved Representatives shall have the right to audit and inspect all inventory of API and Third Party Materials contained at the Facility (or the facility of a Material Third Party Supplier or Subcontractor, as the case may be).  agrees to reasonably cooperate and assist  (and to require any Material Third Party Supplier or Subcontractor to cooperate and assist ) in connection with any audits or inspections pursuant to this Section 9.2. Audits or inspections under this Section 9.2 shall occur during business hours and shall be scheduled by Approved Representatives at least [***] in advance; provided, however, that, in the event of an Adverse Event or any proposed or actual inspection by the FDA or other Governmental Body (whether of  or a Material Third Party Supplier or Subcontractor) or other similar event or emergency involving any API or Third Party Materials, Approved Representatives shall have the right at any time, upon written notice to  (or any Material Third Party Supplier or Subcontractor) of [***], to conduct an audit or inspection of those affected portions of the Facility (or the facility of such Material Third Party Supplier or Subcontractor, as the case may be) used in the manufacture, generation, storage, testing, treatment, holding, transportation, distribution or other handling or receiving of API and Third Party Materials.  shall ensure that Approved Representatives have access to Material Third Party Supplier‚Äôs and Subcontractor‚Äôs facilities in the manner set forth in this Section 9.2.  shall as soon as practicable take any corrective action reasonably requested by  in connection with this Section 9.2.\n",
      "-------------------\n"
     ]
    }
   ],
   "source": [
    "\n",
    "exclude_result_list = []\n",
    "\n",
    "\n",
    "for doc in exp_result_list:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Exclude_clause_concepts_agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    exclude_result_list.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "843418ad-4ce9-410d-98f1-a53680b924df",
   "metadata": {},
   "source": [
    "# save file to excel "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "c413d2b5-d2cb-4a19-9284-12422109aae4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Excel file saved: Extracted_Audit_Clauses.xlsx\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "def save_list_to_excel(data_list, output_file=\"output.xlsx\"):\n",
    "    \"\"\"Converts a list to a Pandas DataFrame and saves it as an Excel file.\"\"\"\n",
    "    df = pd.DataFrame({\"Extracted Clauses\": data_list})  # Convert list to DataFrame\n",
    "    df.to_excel(output_file, index=False)  # Save to Excel\n",
    "    print(f\" Excel file saved: {output_file}\")\n",
    "\n",
    "\n",
    "\n",
    "# Save to Excel\n",
    "save_list_to_excel(exclude_result_list, \"Extracted_Audit_Clauses.xlsx\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "60ea1755-b2e9-45e4-86cf-949a8bb4758a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "539567a9-33b2-4de3-b62b-847cfb7c5648",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5ad5ef54-ad0f-427b-aba5-3d8389800245",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "94b45bbe-8cec-4ffc-80bd-3c86c8ffc8e6",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9573f01e-21c9-4c61-a444-a98c3f1e6285",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d31f073e-f318-4333-a2b6-15c15a60f7f6",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "154ff51d-37b8-4b0d-bd44-07b575d4b529",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "20605ce3-7bd4-4044-b122-e07a9fef83b7",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "40d6ed48-48a3-4539-9983-f9d79c4a0f7b",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a41f4065-bc8f-4ef4-a1d2-210cc359bc14",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "exclude_result_list_1 = []\n",
    "\n",
    "\n",
    "for doc in final_result_list:\n",
    "\n",
    "    messages = {\n",
    "            \"messages\": [\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": doc\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "    \n",
    "    \n",
    "    result = Exclude_clause_concepts_agent.invoke(messages)\n",
    "    \n",
    "    result_content = result[\"messages\"][-1].content\n",
    "    exclude_result_list_1.append(result_content)\n",
    "    print(result_content)\n",
    "    print(\"-------------------\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 288,
   "id": "0df8f8df-926d-401b-9daf-e01113ae5a5d",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "messages_2 = {\n",
    "        \"messages\": [\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"content\": result_2\n",
    "            }\n",
    "        ]\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "id": "e56370a9-3674-4f10-b85f-3790bb925474",
   "metadata": {},
   "outputs": [],
   "source": [
    "result_3 = Expected_key_clause_feature_agent.invoke(messages_2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "id": "6fca420d-040c-40f9-a9ed-b044cc0dc187",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'quality assurance audits, records reviews and other activities under this Agreement through its (or its Affiliates‚Äô) employees or consultants with a bona fide need to know, but only to the extent necessary for the Party to exercise its rights and discharge its obligations under this Agreement,'"
      ]
     },
     "execution_count": 282,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result_4 = result_3[\"messages\"][-1].content\n",
    "result_4"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "id": "849f1104-7003-48ef-8c5f-b5b02d7c1df0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'quality assurance audits, records reviews and other activities under this Agreement through its (or its Affiliates‚Äô) employees or consultants with a bona fide need to know, but only to the extent necessary for the Party to exercise its rights and discharge its obligations under this Agreement,'"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "messages_3 = {\n",
    "        \"messages\": [\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"content\": result_4\n",
    "            }\n",
    "        ]\n",
    "    }\n",
    "\n",
    "result_5 = Exclude_clause_concepts_agent.invoke(messages_3)\n",
    "\n",
    "result_6 = result_5[\"messages\"][-1].content\n",
    "result_6"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e80180fe-a4a2-4356-bdd7-32e2d1656934",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4386cab2-6f20-4327-983b-082f50d35ff7",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5f806723-13e2-4e95-900b-9cade15b329f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e6e04ba7-ac48-4c61-a773-08bcaf776249",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7858301f-2359-4f14-ad93-3c566d572d34",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5de8e919-00b3-406f-ac67-5d314f0ed21d",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0dcec313-9bff-4be9-87f0-64c587e53044",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8659b74a-dff7-48a5-9894-35d7b57f7156",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e8ca9b8b-1ff9-4eae-b712-ba0e889d367f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8e87de66-1c88-489a-906a-8801b1620c54",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (ai_env)",
   "language": "python",
   "name": "ai_env"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
